Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.     )

 

Filed by the Registrant  x

 

Filed by a Party other than the Registrant  o

 

Check the appropriate box:

 o

Preliminary Proxy Statement

 o

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 x

Definitive Proxy Statement

 o

Definitive Additional Materials

o

Soliciting Material Pursuant to §240.14a-12

 

BioSante Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

x

No fee required.

o

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1)

Title of each class of securities to which transaction applies:

 

 

 

 

(2)

Aggregate number of securities to which transaction applies:

 

 

 

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

 

 

(4)

Proposed maximum aggregate value of transaction:

 

 

 

 

(5)

Total fee paid:

 

 

 

o

Fee paid previously with preliminary materials.

o

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1)

Amount Previously Paid:

 

 

 

 

(2)

Form, Schedule or Registration Statement No.:

 

 

 

 

(3)

Filing Party:

 

 

 

 

(4)

Date Filed:

 

 

 

 



Table of Contents

 

 

111 Barclay Boulevard

Lincolnshire, Illinois 60069

 

April 11, 2011

 

Dear Fellow Stockholder:

 

We are pleased to invite you to join us for the BioSante Pharmaceuticals, Inc. Annual Meeting of Stockholders to be held on Thursday, May 26, 2011, at 9:00 a.m., local time, at our corporate office located at 111 Barclay Boulevard, Lincolnshire, Illinois 60069.  Details about the meeting, nominees for election to the Board of Directors and other matters to be acted on at the meeting are presented in the Notice of Annual Meeting of Stockholders and proxy statement that follow.

 

It is important that your shares be represented at the meeting, regardless of the number of shares you hold and whether you plan to attend the meeting in person.  Accordingly, please exercise your right to vote by following the instructions for voting on the Notice Regarding the Availability of Proxy Materials you received for the meeting or, if you received a paper copy of the proxy materials, by completing, signing, dating and returning your proxy card, or by using Internet or telephone voting as described in the proxy statement.

 

We are pleased again this year to take advantage of the Securities and Exchange Commission rules that allow issuers to furnish proxy materials to their stockholders on the Internet.  We believe these rules allow us to provide our stockholders with the information they need, while lowering the costs of delivery and reducing the environmental impact of our meeting.

 

On behalf of BioSante’s Board of Directors and management, it is my pleasure to express our appreciation for your continued support.

 

Sincerely,

 

/s/ Stephen M. Simes

 

 

 

Stephen M. Simes

 

Vice Chairman, President and Chief Executive Officer

 

 

Your vote is important.  Please exercise your right to vote as soon as possible by following the instructions for voting on the Notice Regarding the Availability of Proxy Materials you received for the meeting or, if you received a paper copy of the proxy materials, by completing, signing, dating and returning your proxy card, or by using Internet or telephone voting as described in the proxy statement.  By doing so, you may save us the expense of additional solicitation.

 



Table of Contents

 

 

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 26, 2011

 


 

To the Stockholders of BioSante Pharmaceuticals, Inc.:

 

The Annual Meeting of Stockholders of BioSante Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, May 26, 2011, at 9:00 a.m., local time, at our corporate office located at 111 Barclay Boulevard, Lincolnshire, Illinois 60069, for the following purposes:

 

1.                                     To elect seven persons to serve as directors until our next annual meeting of stockholders or until their respective successors are elected and qualified.

 

2.                                     To consider a proposal to approve the BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan.

 

3.                                     To consider a proposal to ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2011.

 

4.                                     To hold an advisory vote on executive compensation.

 

5.                                     To hold an advisory vote on the frequency of an executive compensation advisory vote.

 

6.                                     To transact such other business as may properly come before the meeting or any adjournment of the meeting.

 

Only stockholders of record at the close of business on April 1, 2011 will be entitled to notice of, and to vote at, the meeting and any adjournments thereof.  A stockholder list will be available at BioSante’s corporate office beginning May 16, 2011 during normal business hours for examination by any stockholder registered on BioSante’s stock ledger as of the record date for any purpose germane to the annual meeting.

 

 

By Order of the Board of Directors,

 

 

 

/s/ Phillip B. Donenberg

 

 

 

Phillip B. Donenberg

 

Senior Vice President of Finance, Chief Financial Officer and Secretary

 

 

April 11, 2011

 

Lincolnshire, Illinois

 

 



Table of Contents

 

TABLE OF CONTENTS

 


 

 

Page

 

 

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS

1

 

 

GENERAL INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

1

Date, Time, Place and Purposes of Meeting

1

Who Can Vote

2

How You Can Vote

2

How the Board of Directors Recommends that You Vote

3

How You May Revoke or Change Your Vote

3

Quorum Requirement

4

Vote Required

4

 

 

STOCK OWNERSHIP

6

Significant Common Stockholders

6

Directors and Executive Officers

7

Significant Class C Stockholders

9

Section 16(a) Beneficial Ownership Reporting Compliance

9

 

 

PROPOSAL NO. 1 — ELECTION OF DIRECTORS

10

Number of Directors

10

Nominees for Director

10

Board Designation Rights

10

Information About Current Directors and Board Nominees

10

Additional Information About Current Directors and Board Nominees

11

Board Recommendation

15

 

 

CORPORATE GOVERNANCE

16

Corporate Governance Guidelines

16

Director Independence

16

Board Leadership Structure

17

Board Meetings and Attendance

17

Board Committees

17

Audit and Finance Committee

18

Compensation Committee

19

Nominating and Corporate Governance Committee

21

Director Nominations Process

23

Board Oversight of Risk

25

Code of Conduct and Ethics

25

Policy Regarding Director Attendance at Annual Meetings of Stockholders

26

Complaint Procedures

26

Process Regarding Stockholder Communications with Board of Directors

26

 

 

DIRECTOR COMPENSATION

27

Summary of Cash and Other Compensation

27

 



Table of Contents

 

 

Page

 

 

Overview of Director Compensation Program

28

Recent Changes to Director Compensation Program

28

Cash Compensation

30

Stock Options

31

Indemnification Agreements

31

 

 

EXECUTIVE COMPENSATION

32

Summary of Cash and Other Compensation

32

Grants of Plan-Based Awards

41

Outstanding Equity Awards at Fiscal Year End

45

Options Exercised and Stock Vested During Fiscal Year

46

Potential Payments Upon Termination or Change in Control

47

 

 

RELATED PERSON RELATIONSHIPS AND TRANSACTIONS

53

Director and Executive Officer Compensation

53

Policies and Procedures Regarding Related Party Transactions

53

 

 

AUDIT-RELATED MATTERS

55

Audit and Finance Committee Report

55

Audit, Audit-Related, Tax and Other Fees

56

Pre-Approval Policies and Procedures

56

 

 

PROPOSAL NO. 2 — APPROVAL OF BIOSANTE PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN

57

Introduction

57

Reasons Why You Should Vote in Favor of the Approval of the Second Amended and Restated 2008 Plan

57

Summary of Sound Governance Features of the Second Amended and Restated 2008 Plan

59

Comparison of Second Amended and Restated 2008 Plan to Current 2008 Plan

61

Purpose of the Second Amended and Restated 2008 Plan

61

Summary of the Second Amended and Restated 2008 Plan

62

Federal Income Tax Consequences

69

Incentive Awards Granted Under the Second Amended and Restated 2008 Plan

71

Securities Authorized for Issuance Under Equity Compensation Plans

72

Board of Directors Recommendation

72

 

 

PROPOSAL NO. 3 — RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

73

Selection of Independent Registered Public Accounting Firm

73

Board Recommendation

73

 

 

PROPOSAL NO. 4 — EXECUTIVE COMPENSATION ADVISORY VOTE

74

Introduction

74

Reasons Why You Should Vote FOR Our Say-on-Pay Vote

74

Proposed Resolution

75

Board Recommendation

75

 

ii



Table of Contents

 

 

Page

 

 

PROPOSAL NO. 5 — ADVISORY VOTE ON THE FREQUENCY OF EXECUTIVE COMPENSATION ADVISORY VOTE

76

Introduction

76

Reasons Why You Should Vote Every Three Years for the Frequency of Our Say-on-Pay Vote

76

Proposed Resolution

76

Board Recommendation

77

 

 

OTHER MATTERS

78

Stockholder Proposals for 2012 Annual Meeting

78

Director Nominations for 2012 Annual Meeting

78

Copies of 2010 Annual Report

79

Householding of Annual Meeting Materials

79

Proxy Solicitation Costs

79

Other Business

79

 

iii



Table of Contents

 

 

111 Barclay Boulevard

Lincolnshire, Illinois 60069

 


 

PROXY STATEMENT FOR
ANNUAL MEETING OF STOCKHOLDERS

 

May 26, 2011

 


 

The Board of Directors of BioSante Pharmaceuticals, Inc. is soliciting your proxy for use at the 2011 Annual Meeting of Stockholders to be held on Thursday, May 26, 2011.  The Board of Directors expects to make available to our stockholders beginning on or about April 11, 2011 the Notice of Annual Meeting of Stockholders, this proxy statement and a form of proxy on the Internet, or send these materials to stockholders.

 

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS

 

Our proxy statement and annual report to stockholders, which includes our annual report on Form 10-K, are available at www.proxyvote.com/BioSante.  Pursuant to rules adopted by the Securities and Exchange Commission, or SEC, we have elected to provide access to our proxy materials over the Internet.  Accordingly, we are sending a Notice Regarding the Availability of Proxy Materials to our stockholders of record and beneficial owners (excluding those stockholders of record and beneficial owners who previously have requested that they receive electronic or paper copies of our proxy materials).  All stockholders have the ability to access our proxy materials on the website referred to in the Notice Regarding the Availability of Proxy Materials or request to receive a printed set of our proxy materials. Instructions on how to access our proxy materials over the Internet or to request a printed copy may be found in the Notice Regarding the Availability of Proxy Materials. In addition, stockholders may request to receive proxy materials in printed form by mail or electronically by e-mail on an ongoing basis.  We believe that this process should expedite your receipt of our proxy materials, lower the costs of our Annual Meeting and reduce the environmental impact of our meeting.

 

GENERAL INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

 

Date, Time, Place and Purposes of Meeting

 

The Annual Meeting of Stockholders of BioSante Pharmaceuticals, Inc. will be held on Thursday, May 26, 2011, at 9:00 a.m., local time, at our corporate office located at 111 Barclay Boulevard,

 

1



Table of Contents

 

Lincolnshire, Illinois 60069 for the purposes set forth in the Notice of Annual Meeting of Stockholders.

 

Who Can Vote

 

Stockholders of record at the close of business on April 1, 2011 will be entitled to notice of and to vote at the meeting or any adjournment of the Annual Meeting.  As of that date, there were 93,590,612 shares of our common stock and 391,286 shares of our class C special stock outstanding.  Each share of our common stock and class C special stock is entitled to one vote on each matter to be voted on at the Annual Meeting.  Stockholders are not entitled to cumulate voting rights.

 

How You Can Vote

 

Your vote is important.  Whether you hold shares directly as a stockholder of record or beneficially in “street name” (through a broker, bank or other nominee), you may vote your shares without attending the Annual Meeting.  You may vote by granting a proxy or, for shares held in street name, by submitting voting instructions to your stockbroker or nominee.

 

If you are a stockholder whose shares are registered in your name, you may vote your shares in person at the meeting or by one of the three following methods:

 

·                  Vote by Internet, by going to the web address http://www.proxyvote.com and following the instructions for Internet voting shown on the Notice of Internet Availability of Proxy Materials or on your proxy card.

 

·                  Vote by Telephone, by dialing 1-800-690-6903 and following the instructions for telephone voting shown on the Notice of Internet Availability of Proxy Materials or on your proxy card.

 

·                  Vote by Proxy Card, by completing, signing, dating and mailing the enclosed proxy card in the envelope provided if you received a paper copy of these proxy materials.  If you vote by Internet or telephone, please do not mail your proxy card.

 

If your shares are held in street name, you may receive a separate voting instruction form or you may need to contact your broker, bank or other nominee to determine whether you will be able to vote electronically using the Internet or telephone.

 

The deadline for voting by telephone or by using the Internet is 11:59 p.m., Eastern Daylight Savings Time, on Wednesday, May 25, 2011.  Please see the Notice of Internet Availability of Proxy Materials, your proxy card or the information your bank, broker or other holder of record provided to you for more information on your options for voting.

 

If you return your signed proxy card or use Internet or telephone voting before the Annual Meeting, the named proxies will vote your shares as you direct.

 

For Proposal No. 1—Election of Directors, you may:

 

·                  Vote FOR all seven of the nominees for director,

 

·                  WITHHOLD your vote from all seven of the nominees for director or

 

2



Table of Contents

 

·                  WITHHOLD your vote from one or more of the seven nominees for director that you designate.

 

For Proposal No. 2—Approval of BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan, Proposal No. 3—Ratification of Selection of Independent Registered Public Accounting Firm and Proposal No. 4—Executive Compensation Advisory Vote, you may:

 

·                  Vote FOR the proposal,

 

·                  Vote AGAINST the proposal or

 

·                  ABSTAIN from voting on the proposal.

 

For Proposal No. 5—Advisory Vote on the Frequency of Executive Compensation Advisory Vote, you may vote for a frequency of every year, every two years or every three years, or you may abstain from voting on the proposal.

 

If you send in your proxy card or use Internet or telephone voting, but you do not specify how you want to vote your shares, the proxies will vote your shares FOR all seven of the nominees for director in Proposal No. 1— Election of Directors, FOR Proposal No. 2— Approval of BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan, FOR Proposal No. 3—Ratification of Selection of Independent Registered Public Accounting Firm, FOR Proposal No. 4—Executive Compensation Advisory Vote and for a frequency of every THREE YEARS on Proposal No. 5—Advisory Vote on the Frequency of Executive Compensation Advisory Vote.

 

How the Board of Directors Recommends that You Vote

 

The Board of Directors unanimously recommends that you vote:

 

·                  FOR all seven of the nominees for director in Proposal No. 1—Election of Directors;

 

·                  FOR Proposal No. 2—Approval of BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan;

 

·                  FOR Proposal No. 3—Ratification of Selection of Independent Registered Public Accounting Firm;

 

·                  FOR Proposal No. 4—Executive Compensation Advisory Vote; and

 

·                  for a frequency of every THREE YEARS on Proposal No. 5—Advisory Vote on the Frequency of Executive Compensation Advisory Vote.

 

How You May Revoke or Change Your Vote

 

If you are a stockholder whose shares are registered in your name, you may revoke your proxy at any time before it is voted by one of the following methods:

 

·                  Submitting another proper proxy with a more recent date than that of the proxy first given by following the Internet or telephone voting instructions or completing, signing, dating and returning a proxy card to us;

 

3



Table of Contents

 

·                  Sending written notice of revocation to our Corporate Secretary; or

 

·                  Attending the Annual Meeting and voting by ballot.

 

If you hold your shares through a broker, bank or other nominee, you may revoke your proxy by following instructions your broker, bank or other nominee provides.

 

Quorum Requirement

 

The presence at the Annual Meeting, in person or by proxy, of the holders of a majority (46,795,307 shares) of the outstanding shares of our common stock and a majority (195,644 shares) of the outstanding shares of our class C special stock as of the record date will constitute a quorum for the transaction of business at the Annual Meeting.  In general, shares of our common stock and shares of our class C special stock represented by a properly signed and returned proxy card will be counted as shares present and entitled to vote at the Annual Meeting for purposes of determining a quorum.  Shares represented by proxies marked “Abstain” and “broker non-votes” are counted in determining whether a quorum is present.  A “broker non-vote” is a proxy returned by a broker on behalf of its beneficial owner customer that is not voted on a particular matter because voting instructions have not been received by the broker from the customer, and the broker does not have discretionary authority to vote on behalf of such customer on such matter.  If there is not a quorum, a majority of the shares present at the annual meeting may adjourn the annual meeting to a later date as discussed below under “Discretionary Voting and Adjournments.”

 

Vote Required

 

Assuming a quorum is represented at the Annual Meeting, either in person or by proxy, the following vote is required for each of the following matters:

 

·                  Proposal No. 1—Election of Directors requires the affirmative vote of a plurality of the shares of our common stock and class C special stock, present in person or by proxy and entitled to vote, voting together as a single class.

 

·                  Proposal No. 2— Approval of BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan requires the affirmative vote of the holders of a majority of the shares of our common stock and class C special stock, present in person or by proxy and entitled to vote, voting together as a single class.  In addition, under the Listing Rules of the NASDAQ Stock Market, the approval of the BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan requires the affirmative vote of a majority of the total votes cast on the proposal.

 

·                  Proposal No. 3—Ratification of Selection of Independent Registered Public Accounting Firm requires the affirmative vote of a majority of our common stock and class C special stock, present in person or by proxy and entitled to vote, voting together as a single class.

 

·                  Proposal No. 4—Executive Compensation Advisory Vote requires the affirmative vote of a majority of our common stock and class C special stock, present in person or by proxy and entitled to vote, voting together as a single class.  Although this is a non-binding, advisory vote, our Compensation Committee and Board expect to take into account the outcome of the vote when considering future executive compensation decisions.

 

4



Table of Contents

 

·                  Proposal No. 5— Advisory Vote on the Frequency of Executive Compensation Advisory Vote will be decided by the affirmative vote of a plurality of shares of our common stock and class C special stock, present in person or by proxy and entitled to vote, voting together as a single class.  A “plurality” for Proposal No. 5 means the choice of frequency that receives the greatest number of votes cast. Although this is a non-binding, advisory vote, our Compensation Committee and Board expect to take into account the outcome of the vote when considering the frequency of future executive compensation advisory votes.

 

If your shares are held in “street name” and you do not indicate how you wish to vote, your broker is permitted to exercise its discretion to vote your shares on certain “routine” matters.  The only routine matter to be submitted to our stockholders at the Annual Meeting is Proposal No. 3—Ratification of Selection of Independent Registered Public Accounting Firm.  None of our other four proposals are routine matters.  Accordingly, if you do not direct your broker how to vote for a director in Proposal No. 1 or how to vote for Proposal No. 2, Proposal No. 4 or Proposal No. 5, your broker may not exercise discretion and may not vote your shares on that proposal.

 

For purposes of Proposal No. 1, Proposal No. 2, Proposal No. 4 and Proposal No. 5, broker non-votes are considered to be shares represented by proxy at the meeting but are not considered to be shares “entitled to vote” or “votes cast” at the meeting.  As such, a broker non-vote will not be counted as a vote “For” or “Withheld” with respect to a director in Proposal No. 1, a vote “For” or “Against” Proposal No. 2 or Proposal No. 4 or a vote for a frequency of every year, every two years or every three years in Proposal No. 5; and, therefore, will have no effect on the outcome of the vote on any such proposal.  Proxies marked “Abstain” will be counted in determining the total number of shares “entitled to vote” and “votes cast” on each of the proposals and will have the effect of a vote “Against” a proposal, except for Proposal No. 5, where the abstention will have no effect on the outcome of the vote.

 

Who Will Count the Votes

 

Phillip B. Donenberg, our Senior Vice President of Finance, Chief Financial Officer and Secretary will tabulate stockholder votes and act as our independent inspector of elections for the Annual Meeting.

 

Discretionary Voting and Adjournments

 

We currently are unaware of any business to be acted upon at the Annual Meeting other than that described in this proxy statement. If, however, other matters properly are brought before the Annual Meeting, or any adjournment or postponement of the Annual Meeting, your proxy includes discretionary authority on the part of the individuals appointed to vote your common stock or class C special stock or act on those matters according to their best judgment, including to adjourn the Annual Meeting.

 

Adjournment of the Annual Meeting may be made for the purpose of, among other things, soliciting additional proxies. Any adjournment may be made from time to time by approval of the holders of common stock and class C special stock, voting together as a single class, representing a majority of the votes present in person or by proxy at the Annual Meeting, whether or not a quorum exists, without further notice other than by an announcement made at the Annual Meeting.

 

5



Table of Contents

 

STOCK OWNERSHIP

 


 

Significant Common Stockholders

 

The table below sets forth information as to individuals and entities that have reported to the SEC or have advised us that they are a beneficial owner, as defined by the SEC’s rules and regulations, of more than five percent of our outstanding common stock.

 

 

 

Shares Beneficially Owned

 

Name and Address of

 

Common Stock

 

Class C Special Stock

 

Common Stock
and Common
Stock

 

Percent of
Total
Voting

 

Beneficial Owner

 

Number

 

Percent

 

Number

 

Percent

 

Equivalents

 

Power(1)

 

Great Point Partners LLC
165 Mason Street, 3rd Floor
Greenwich, CT 06830

 

7,909,706

(2)

8.5

%

 

 

7,909,706

 

8.5

%

 


*

 

Represents beneficial ownership of less than one percent.

 

 

 

(1)

 

In calculating the percent of total voting power, the voting power of shares of our common stock and shares of our class C special stock is combined.

 

 

 

(2)

 

According to a Schedule 13G/A filed with the SEC on February 14, 2011, Great Point Partners, LLC owns 7,909,706 shares of our common stock. The ownership consists of 2,317,442 shares owned by Biomedical Value Fund, LP (“BVF”), 2,229,854 shares owned by Biomedical Offshore Value Fund, Ltd. (“BOVF”), 719,770 shares owned by Biomedical Institutional Value Fund, LP (“BIVF”), 837,696 shares owned by Lyrical Multi-Manager Fund, LP (“Lyrical”), 1,396,159 shares owned by Class D Series of GEF-PS, LP (“GEF-PS”), 55,845 shares owned by David J. Morrison (“Morrison”) and 352,940 shares owned by WS Investments III, LLC (“WS”). Does not include 1,077,763 shares underlying a warrant held by BVF, 995,945 shares underlying a warrant held by BOVF, 308,277 shares underlying a warrant held by BIVF, 433,526 shares underlying a warrant held by Lyrical, 722,543 shares underlying a warrant held by GEF-PS, 28,901 shares underlying a warrant held by Morrison and 176,470 shares underlying a warrant held by WS. The provisions of such warrants restrict the exercise of such warrants to the extent that, after giving effect to such exercise, the holder of the warrants and its affiliates and any other person or entities with which such holder would constitute a group would beneficially own in excess of 9.99 percent of the number of shares of our common stock outstanding immediately after giving effect to such exercise. Great Point Partners, LLC is the investment manager of each of BVF, BOVF, BIVF, Lyrical, GEF-PS, Morrison and WS and by virtue of such status may be deemed to be the beneficial owner of such shares. Each of Dr. Jeffrey R. Jay, M.D., as senior managing member of Great Point Partners, LLC, and Mr. David Kroin, as special managing member of Great Point Partners, LLC, has voting and dispositive power with respect to such shares, and therefore may be deemed to be the beneficial owners of such shares. Notwithstanding the foregoing, each of Great Point Partners, LLC, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

 

6



Table of Contents

 

Directors and Executive Officers

 

The table below sets forth information known to us regarding the beneficial ownership of each class of our capital stock as of April 1, 2011 for:

 

·                  each of our directors and nominees for directors;

 

·                  each of the executive officers named in the Summary Compensation Table under the heading “Executive Compensation—Summary of Cash and Other Compensation” (we collectively refer to these persons as our “named executive officers”); and

 

·                  all of our current directors and executive officers as a group.

 

The number of shares beneficially owned by a person includes shares subject to options held by that person that are currently exercisable or that become exercisable within 60 days of April 1, 2011.  Percentage calculations assume, for each person and group, that all shares that may be acquired by such person or group pursuant to options currently exercisable or that become exercisable within 60 days of April 1, 2011 are outstanding for the purpose of computing the percentage of common stock owned by such person or group.  However, such unissued shares of common stock described above are not deemed to be outstanding for calculating the percentage of common stock owned by any other person.

 

Except as otherwise indicated, the persons in the table below have sole voting and investment power with respect to all shares of capital stock shown as beneficially owned by them, subject to community property laws where applicable and subject to the information contained in the notes to the table.  Unless otherwise indicated, the address for each of the individuals in the table below is c/o BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, IL 60069.

 

 

 

Shares Beneficially Owned(1)(2)

 

Name and Address of

 

Common Stock

 

Class C Special Stock

 

Common Stock
and Common
Stock

 

Percent of
Total
Voting

 

Beneficial Owner

 

Number

 

Percent

 

Number

 

Percent

 

Equivalents

 

Power(3)

 

Louis W. Sullivan, M.D.

 

167,898

 

*

 

100,000

 

25.6

%

267,898

 

*

 

Stephen M. Simes

 

1,108,848

(4)

1.2

%

 

 

1,108,848

 

1.2

%

Fred Holubow

 

181,259

 

*

 

 

 

181,259

 

*

 

Peter Kjaer

 

154,425

 

*

 

 

 

154,425

 

*

 

Ross Mangano

 

2,380,416

(5)

2.5

%

 

 

2,380,416

 

2.5

%

Edward C. Rosenow, III, M.D.

 

137,540

 

*

 

 

 

137,540

 

*

 

John T. Potts, Jr., M.D.

 

19,331

(6)

*

 

 

 

19,331

 

*

 

Stephen A. Sherwin, M.D.

 

218,869

 

*

 

 

 

218,869

 

*

 

Phillip B. Donenberg

 

519,767

 

*

 

 

 

519,767

 

*

 

Michael C. Snabes, M.D., Ph.D.

 

191,667

 

*

 

 

 

191,667

 

*

 

All directors and executive officers as a group (10 persons)

 

5,080,020

(7)

5.3

%

100,000

 

25.6

%

5,180,020

 

5.4

%

 


*

 

Represents beneficial ownership of less than one percent.

 

7



Table of Contents

 

(1)

 

Includes for the persons listed below the following shares subject to options held by that person that are currently exercisable or become exercisable within 60 days of April 1, 2011:

 

Name

 

Shares Underlying
Stock Options

 

Directors

 

 

 

Louis W. Sullivan, M.D.

 

130,000

 

Stephen M. Simes

 

906,581

 

Fred Holubow

 

120,000

 

Peter Kjaer

 

120,000

 

Ross Mangano

 

120,000

 

Edward C. Rosenow, III, M.D.

 

120,000

 

John T. Potts, Jr., M.D.

 

13,750

 

Stephen A. Sherwin, M.D.

 

132,109

 

Named Executive Officers

 

 

 

Stephen M. Simes

 

906,581

 

Phillip B. Donenberg

 

477,445

 

Michael C. Snabes, M.D., Ph.D.

 

191,667

 

All directors and executive officers as a group (10 persons)

 

2,331,552

 

 

(2)

 

Includes shares held by the following persons in securities brokerage accounts, which in certain circumstances under the terms of the standard brokerage account form may involve a pledge of such shares as collateral: Dr. Sullivan (10,000 shares), Mr. Simes (94,728 shares), Mr. Holubow (61,259 shares), Mr. Mangano (66,800 shares), Dr. Rosenow (17,000 shares), Dr. Sherwin (86,760 shares) and Mr. Donenberg (42,322 shares).

 

 

 

(3)

 

In calculating the percent of total voting power, the voting power of shares of our common stock and shares of our class C special stock is combined.

 

 

 

(4)

 

Mr. Simes’s beneficial ownership includes 202,167 shares of common stock held by Mr. Simes’s trust and 100 shares of common stock held by Mr. Simes’s child.

 

 

 

(5)

 

Mr. Mangano’s beneficial ownership includes: (1) 1,929,661 shares of common stock held by JO & Co., of which Mr. Mangano is President; (2) 30,000 shares of common stock held by Oliver & Co., of which Mr. Mangano is the trustee; and (3) an aggregate of 214,999 shares of common stock held in various accounts, of which Mr. Mangano is an advisor and/or a trustee. Mr. Mangano has sole voting and investment power over these shares.

 

 

 

(6)

 

Includes 2,924 shares of common stock held in irrevocable trusts for Dr. Potts’s children, as to which Dr. Potts disclaims any beneficial ownership.

 

 

 

(7)

 

The amount beneficially owned by all current directors and executive officers as a group includes 2,331,552 shares issuable upon the exercise of stock options held by these individuals, 210,575 shares held in trusts and 100 shares held by immediate family members of the directors and executive officers. See notes (1), (4), (5) and (6) above.

 

8



Table of Contents

 

Significant Class C Stockholders

 

The table below sets forth information as to each individual or entity that to our knowledge is a beneficial owner, as defined by the SEC’s rules and regulations, of more than five percent of our outstanding class C special stock.

 

 

 

Shares Beneficially Owned

 

Name and Address of

 

Common Stock

 

Class C Special Stock

 

Common Stock
and Common
Stock

 

Percent of
Total
Voting

 

Beneficial Owner

 

Number

 

Percent

 

Number

 

Percent

 

Equivalents

 

Power(1)

 

Hans Michael Jebsen
c/o Jebsen 7 Co., Ltd.
28/F Caroline Center
28 Yun Ping Road
Causeway Bay, Hong Kong
China

 

425,000

 

*

 

100,000

 

25.6

%

525,000

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marcus Jebsen
c/o Jebsen 7 Co., Ltd.
28/F Caroline Center
28 Yun Ping Road
Causeway Bay, Hong Kong
China

 

125,000

 

*

 

50,000

 

12.8

%

175,000

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Angela Ho
c/o Jet Asia Ltd.
39/F Shun Tak Center
200 Connaught Road Central
Hong Kong, China

 

80,000

 

*

 

100,000

 

25.6

%

180,000

 

*

 

 


*

 

Represents beneficial ownership of less than one percent.

 

 

 

(1)

 

In calculating the percent of total voting power, the voting power of shares of our common stock and shares of our class C special stock is combined.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers and all persons who beneficially own more than 10 percent of the outstanding shares of our common stock to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock.  Directors, executive officers and greater than 10 percent beneficial owners also are required to furnish us with copies of all Section 16(a) forms they file.  To our knowledge, based on review of the copies of such reports and amendments to such reports furnished to us with respect to the year ended December 31, 2010, and based on written representations by our directors and executive officers, all required Section 16 reports under the Securities Exchange Act of 1934, as amended, for our directors, executive officers and beneficial owners of greater than 10 percent of our common stock were filed on a timely basis during the year ended December 31, 2010.

 

9



Table of Contents

 

PROPOSAL NO. 1 — ELECTION OF DIRECTORS

 


 

Number of Directors

 

Our bylaws provide that the Board of Directors will consist of at least one member, or such other number as may be determined by the Board of Directors or our stockholders.  The Board of Directors has fixed the number of directors at seven, effective as of the date of the Annual Meeting.

 

Nominees for Director

 

The Board of Directors has nominated the following seven individuals to serve as our directors until the next annual meeting of our stockholders or until their successors are elected and qualified.  All of the nominees named below are current members of the Board of Directors.

 

·                  Louis W. Sullivan, M.D.

·                  Stephen M. Simes

·                  Fred Holubow

·                  Ross Mangano

·                  Edward C. Rosenow III, M.D.

·                  John T. Potts, Jr., M.D.

·                  Stephen A. Sherwin, M.D.

 

Peter Kjaer, a current director, is not standing for re-election at our 2011 annual meeting of stockholders.  Mr. Kjaer will continue to serve as a director of our company until the 2011 annual meeting of stockholders.  The Board of Directors thanks Mr. Kjaer for his many years of service to the Board.

 

Proxies only can be voted for the number of persons named as nominees in this proxy statement, which is seven.

 

Board Designation Rights

 

Under an employment letter agreement we entered into with Mr. Simes in connection with his acceptance of our offer of employment as an executive officer of our company, Mr. Simes agreed to serve as a director of our company and we agreed to nominate him as a nominee for director and solicit proxies for his election so long as Mr. Simes is employed by us.

 

Information About Current Directors and Board Nominees

 

The table below sets forth certain information that has been furnished to us by each current director and each individual who has been nominated by the Board of Directors to serve as a director of our company.  Peter Kjaer is not standing for re-election at our 2011 annual meeting of stockholders.

 

Name

 

Age

 

Principal Occupation

 

Director
Since

Louis W. Sullivan, M.D.(1)(2)(3)

 

77

 

President Emeritus of the Morehouse School of Medicine and Chairman of the Board of Directors of BioSante

 

1996

 

10



Table of Contents

 

Name

 

Age

 

Principal Occupation

 

Director
Since

Stephen M. Simes

 

59

 

Vice Chairman, President and Chief Executive Officer of BioSante

 

1998

 

 

 

 

 

 

 

Fred Holubow(1)(3)

 

72

 

Managing Director of William Harris Investors, Inc.

 

1999

 

 

 

 

 

 

 

Peter Kjaer

 

51

 

President and Chief Executive Officer of Jet-Asia Ltd.

 

1999

 

 

 

 

 

 

 

Ross Mangano(1)(2)(3)

 

65

 

President of Oliver Estate, Inc.

 

1999

 

 

 

 

 

 

 

John T. Potts, Jr., M.D.

 

79

 

Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School

 

2009

 

 

 

 

 

 

 

Edward C. Rosenow III, M.D.(2)(3)

 

76

 

Master Fellow of the American College of Physicians and the American College of Chest Physicians

 

1997

 

 

 

 

 

 

 

Stephen A. Sherwin, M.D.(2)

 

62

 

Chairman of the Board and Co-Founder of Ceregene, Inc.

 

2009

 


(1)          Member of the Audit and Finance Committee

(2)          Member of the Compensation Committee

(3)          Member of the Nominating and Corporate Governance Committee

 

Additional Information About Current Directors and Board Nominees

 

The paragraphs below provide information about each current director and nominee for director, including all positions he holds, his principal occupation and business experience for the past five years, and the names of other publicly-held companies of which he currently serves as a director or served as a director during the past five years.  We believe that all of our current directors and director nominees display personal and professional integrity; satisfactory levels of education and/or business experience; broad-based business acumen; an appropriate level of understanding of our business and its industry and other industries relevant to our business; the ability and willingness to devote adequate time to the work of the Board of Directors and its committees; a fit of skills and personality with those of our other directors that helps build a board of directors that is effective, collegial and responsive to the needs of our company; strategic thinking and a willingness to share ideas; a diversity of experiences, expertise and background; and the ability to represent the interests of all of our stockholders.  The information presented below regarding each director and nominee for director also sets forth specific experience, qualifications, attributes and skills that led the Board of Directors to the conclusion that he should serve as a director in light of our business and structure.

 

The Honorable Louis W. Sullivan, M.D. has been our Chairman of the Board since 1998 and has been a director of our company since its formation.  Dr. Sullivan served as Secretary of Health and Human Services in the cabinet of President George H.W. Bush from 1989 to 1993.  Since retiring from the Bush Administration, Dr. Sullivan has been associated with the Morehouse School of Medicine in Atlanta, Georgia.  Currently, he serves as President Emeritus and he previously served as President and Dean of the School from 1981 to 1985 and as President from 1985 to 1989 and from 1993 to

 

11



Table of Contents

 

2002.  Dr. Sullivan serves on the board of directors of Henry Schein Inc., United Therapeutics Corporation and Emergent BioSolutions Inc.  Dr. Sullivan also serves as chairman of the National Health Museum in Atlanta, Georgia and as chairman of the Sullivan Alliance to Increase Diversity in the Health Profession.  Dr. Sullivan previously served on the boards of directors of Inhibitex, Inc., 3M Corp., Bristol-Myers Squibb Company, Cigna Corporation and Georgia Pacific Corp.

 

Dr. Sullivan is an experienced public company director having served as a member of the boards of directors of several large and small public companies.  As such, Dr. Sullivan contributes an enhanced knowledge of public company requirements and issues to our Board of Directors, including corporate governance matters, which are specifically relevant to his role as our Chairman of the Board and as a member of our Nominating and Corporate Governance Committee, and executive compensation matters, which are relevant to his role as Chair of our Compensation Committee.  As our longest serving director having served as a director of our company for over 14 years, Dr. Sullivan has a deep and meaningful knowledge of our company, business and industry, all of which we believe is helpful and gives important perspective to our Board of Directors.  Finally, Dr. Sullivan is a medical doctor and thus adds medical expertise to our Board of Directors.

 

Stephen M. Simes has served as our Vice Chairman, President and Chief Executive Officer and a director of our company since 1998.  From 1994 to 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc., (currently a wholly owned subsidiary of Abbott Laboratories) a company with a product focus on infectious diseases, AIDS, endocrinology and oncology.  From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes’s career in the pharmaceutical industry started in 1974 with G.D. Searle & Co. (now a part of Pfizer Inc.).  Mr. Simes currently serves as our designee on the board of directors of Ceregene, Inc., a privately-held biotechnology company focused on the treatment of major neurodegenerative disorders.

 

We believe Mr. Simes’s qualifications to serve as a member of our Board of Directors include his extensive depth of knowledge of our company, business, management and employees and our company’s day-to-day operations which he has gained through his position as President and Chief Executive Officer of our company for over 13 years.  As both a member of our executive team and Board of Directors, Mr. Simes provides a critical link between management and our Board of Directors, enabling our Board of Directors to perform its oversight function with the benefits of management’s perspectives on the business.  In addition, Mr. Simes’s extensive experience and knowledge of the pharmaceutical industry as a result of his previous executive positions with other pharmaceutical companies, as well as our company, and his involvement with the pharmaceutical industry for over 35 years add tremendous value to our Board of Directors.  Mr. Simes has substantial U.S. Food and Drug Administration (FDA) regulatory and licensing experience which he has gained through his prior positions with other pharmaceutical companies and experience with our company, and which has been particularly important to our company and his service on our Board of Directors.

 

Fred Holubow has been a director of our company since 1999.  Since 2001, Mr. Holubow has been a Managing Director of William Harris Investors, Inc., a registered investment advisory firm.  From 1982 to 2001, Mr. Holubow served as Vice President of Pegasus Associates, a registered investment advisory firm he co-founded.  He specializes in analyzing and investing in pharmaceutical and biotechnology companies.  Mr. Holubow previously served on the boards of directors of Micrus

 

12



Table of Contents

 

Endovascular Corporation, ThermoRetec Corporation, Savient Pharmaceuticals, Inc. (formerly Bio-Technology General Corp.), Gynex Pharmaceuticals, Inc. and Unimed Pharmaceuticals, Inc.

 

We believe Mr. Holubow’s qualifications to serve as a member of our Board of Directors include his significant experience of analyzing and investing in pharmaceutical and biotechnology companies both in his current position as Managing Director of William Harris Investors and in his prior position as Vice President of Pegasus Associates.  In addition, through his experience of serving on the boards of directors and more specifically the audit committees of several other public companies, Mr. Holubow has developed a substantial financial and accounting expertise with pharmaceutical and biotechnology companies, which he contributes to our Board of Directors and more specifically to our Audit and Finance Committee in his role as Chair of our Audit and Finance Committee.

 

Peter Kjaer has been a director of our company since 1999.  Mr. Kjaer has been President and Chief Executive Officer of Jet-Asia Ltd., a Hong Kong-based aircraft and management company, since 1996.

 

We believe Mr. Kjaer’s qualifications to serve as a member of our Board of Directors include his general business experience.   Peter Kjaer is not standing for re-election at our 2011 annual meeting of stockholders.

 

Ross Mangano has been a director of our company since 1999.  Mr. Mangano has been the President and a director of Oliver Estate, Inc., a management company specializing in investments in public and private companies, since 1971.  Mr. Mangano in the past has served on the boards of directors of Cerprobe Corporation, Tower Federal Savings & Loan, Cypress Communications, Inc. and Mego Financial Corp.

 

We believe Mr. Mangano’s qualifications to serve as a member of our Board of Directors include his significant general business experience as President of Oliver Estate, Inc. and his significant experience analyzing and investing in public and private companies.  In addition, we believe Mr. Mangano provides our Board of Directors valuable business, leadership and management experience and insights into many aspects of our business.  Mr. Mangano is President of JO & Co., which is a significant stockholder of our company, and controls all voting and investment power with respect to shares of our common stock held by JO & Co., which we believe gives him and our Board of Directors the perspective of a significant stockholder in making decisions.

 

John T. Potts, Jr., M.D. has been a director of our company since October 2009 when he was elected to our board of directors in connection with our merger with Cell Genesys, Inc.  His career spans more than 40 years of service in science and medicine.  Dr. Potts is currently the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School.  After medical training at the University of Pennsylvania, he did his internship and residency at Massachusetts General Hospital (MGH) from 1957 to 1959, then went to the National Institutes of Health (NIH) to work with Nobel laureate Christian Anfinsen in protein chemistry.  Dr. Potts remained at the NIH from 1959 to 1968, when he returned to the MGH as chief of endocrinology.  He served as chairman of the Department of Medicine and physician-in-chief from 1981 to 1996.  In his role as director of research from 1995 to 2004, Dr. Potts was responsible for developing policies and strategies for preserving and strengthening the extensive scientific research effort at MGH, an endeavor which he continues to the present.  The author or co-author of more than 500 scientific publications, he is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences.  Dr. Potts is a director of Zeltiq Aesthetics, a founder of Radius Health, Inc., and a member of the Scientific Advisory Boards of Radius Health, Inc., MPM Capital and HealthCare Ventures. 

 

13



Table of Contents

 

During the past five years, Dr. Potts previously served on the boards of directors of Cell Genesys, Inc. and Celltaxsys.

 

We believe Dr. Potts’s qualifications to serve as a member of our Board of Directors include his prior experience as a director of Cell Genesys, Inc. and his familiarity with our cancer vaccines and the other technologies we acquired as a result of our merger with Cell Genesys.  Dr. Potts is a well accomplished endocrinologist and thus has significant experience and interest in the industry in which our company participates.

 

Edward C. Rosenow, III, M.D. has been a director of our company since 1997.  Dr. Rosenow is a Master Fellow of the American College of Physicians as well as Master Fellow of the American College of Chest Physicians.  Dr. Rosenow was the Arthur M. and Gladys D. Gray Professor of Medicine at the Mayo Clinic from 1988 until his retirement in 1996.  Beginning with his residency in 1960, Dr. Rosenow has worked at the Mayo Clinic in many professional capacities including as a Consultant in Internal Medicine (Thoracic Diseases) from 1966 to 1996, an Assistant Professor, Associate Professor and Professor of Medicine at the Mayo Clinic Medical School, President of the Mayo Clinic Staff in 1986, and Chair of the Division of Pulmonary and Critical Care Medicine from 1987 to 1994.  In 1994, Dr. Rosenow received the Mayo Distinguished Clinician Award.  Dr. Rosenow also has served as a consultant to NASA, space station FREEDOM at the Johnson Space Center in Houston, Texas from 1989 to 1990 and as the President of the American College of Chest Physicians from 1989 to 1990.  In 1998, he received the Mayo Distinguished Alumnus Award.  In 2007, Dr. Rosenow was awarded a named professorship, the Edward C. Rosenow III, M.D. Professorship in the Art of Medicine at the Mayo Clinic School of Medicine, given by Bruce, Martha and Zylpha Clinton.  In 2009, he received the Plummer Society Award for Excellence in Medicine.

 

We believe Dr. Rosenow’s qualifications to serve as a member of our Board of Directors include his significant prior experience as a medical doctor and his interest in the industry in which our company participates.  As our second longest serving director having served as a director of our company for over 13 years, Dr. Rosenow has a deep and meaningful knowledge of our company, business and industry, all of which we believe is helpful to our Board of Directors.

 

Stephen A. Sherwin, M.D. has been a director of our company since October 2009 when he was elected to our board of directors in connection with our merger with Cell Genesys, Inc.  Dr. Sherwin is currently chairman of the board of directors of Ceregene, Inc., a company which he co-founded in 2001.  Dr. Sherwin served as chief executive officer and a director of Cell Genesys, Inc. from the beginning of company operations in 1990 to October 2009 and as chairman of the board from 1994 to October 2009.  From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., most recently as vice president of clinical research.  Prior to 1983, Dr. Sherwin was on the staff of the National Cancer Institute.  Dr. Sherwin also was a co-founder of Abgenix, Inc, an antibody company, which was acquired by Amgen in 2006.  He also is a director of Biogen Idec, Inc., Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc. and also currently serves as chairman of the board of the Biotechnology Industry Organization (BIO).  Dr. Sherwin holds a B.A. in biology from Yale University, an M.D. from Harvard Medical School and is board-certified in internal medicine and medical oncology.  During the past five years, Dr. Sherwin previously served on the board of directors of Cell Genesys, Inc.

 

We believe Dr. Sherwin’s qualifications to serve as a member of our Board of Directors include his prior experience as chief executive officer of Cell Genesys, Inc. and his familiarity with our cancer vaccines and other technologies we acquired from Cell Genesys.  Dr. Sherwin has extensive knowledge of the life sciences industry and brings to our Board of Directors more than 25 years of

 

14



Table of Contents

 

experience in senior leadership positions at large and small publicly traded life sciences companies and as chairman of the board of BIO.  Dr. Sherwin’s medical expertise in internal medicine and oncology provides a unique contribution to our Board of Directors.  As an experienced public company director and executive, Dr. Sherwin contributes an enhanced knowledge of public company requirements and issues, including corporate governance matters, which are specifically relevant to his role as Chair of our Nominating and Corporate Governance Committee, and executive compensation matters, which are relevant to his service as a member of our Compensation Committee.

 

Board Recommendation

 

The Board of Directors unanimously recommends a vote FOR the election of all of the seven nominees for director named in the proxy statement.

 

If prior to the Annual Meeting, the Board of Directors should learn that any nominee will be unable to serve for any reason, the proxies that otherwise would have been voted for this nominee will be voted for a substitute nominee as selected by the Board of Directors.  Alternatively, the proxies, at the discretion of the Board of Directors, may be voted for that fewer number of nominees as results from the inability of any nominee to serve.  The Board of Directors has no reason to believe that any of the nominees will be unable to serve.

 

15



Table of Contents

 

CORPORATE GOVERNANCE

 


 

Corporate Governance Guidelines

 

The Board of Directors has adopted Corporate Governance Guidelines.  A copy of these Corporate Governance Guidelines can be found on the Investors—Corporate Governance section of our corporate website at www.biosantepharma.com.  Among the topics addressed in our Corporate Governance Guidelines are:

 

·                  Board size, composition and qualifications;

·                  Selection of directors;

·                  Board leadership;

·                  Board committees;

·                  Board and committee meetings;

·                  Executive sessions of outside directors;

·                  Meeting attendance by directors and non-directors;

·                  Appropriate information and access;

·                  Ability to retain advisors;

·                  Conflicts of interest;

·                  Board interaction with corporate constituencies;

·                  Change of principal occupation and board memberships;

·                  Retirement and term limits;

·                  Board compensation;

·                  Stock ownership by directors and executive officers;

·                  Loans to directors and executive officers;

·                  CEO evaluation;

·                  Board evaluation;

·                  Director continuing education; and

·                  Succession planning.

 

Director Independence

 

The Board of Directors has determined affirmatively that seven of our eight current directors — Louis W. Sullivan, M.D., Fred Holubow, Peter Kjaer, Ross Mangano, Edward C. Rosenow III, M.D., John T. Potts, Jr., M.D. and Stephen A. Sherwin, M.D. — are “independent directors” under the Listing Rules of the NASDAQ Stock Market.  The Listing Rules of the NASDAQ Stock Market provide a non-exclusive list of persons who are not considered independent.  For example, under these rules, a director who is, or during the past three years was, employed by the company or by any parent or subsidiary of the company, other than prior employment as an interim chairman or chief executive officer, would not be considered independent.  No director qualifies as independent unless the Board of Directors affirmatively determines that the director does not have a material relationship with the listed company that would interfere with the exercise of independent judgment.  In making an affirmative determination that a director is an “independent director,” the Board of Directors reviewed and discussed information provided by these individuals and by us with regard to each of their business and personal activities as they may relate to us and our management.

 

16



Table of Contents

 

Board Leadership Structure

 

The Board of Directors believes that our stockholders are best served if the Board of Directors retains the flexibility to adapt its leadership structure to applicable facts and circumstances, which necessarily change over time.  Accordingly, under our Corporate Governance Guidelines, the office of Chairman of the Board and Chief Executive Officer may or may not be held by one person.  The Board of Directors believes it is best not to have a fixed policy on this issue and that it should be free to make this determination based on what it believes is best under the circumstances.  However, the Board of Directors strongly endorses the concept of an independent director being in a position of leadership for the rest of the outside directors.  Under our Corporate Governance Guidelines, if at any time the Chief Executive Officer and Chairman of the Board positions are held by the same person, the Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, will elect an independent director as a lead independent director.

 

Louis W. Sullivan, M.D. currently serves as our non-executive Chairman of the Board.  Stephen M. Simes currently serves as our Vice Chairman, President and Chief Executive Officer.  Because the Chief Executive Officer and Chairman of the Board positions currently are not held by the same person, we do not have a lead independent director.  We currently believe this leadership structure is in the best interests of our company and our stockholders and strikes the appropriate balance between the Chief Executive Officer’s responsibility for the strategic direction, day-to-day-leadership and performance of our company and the Chairman’s responsibility to provide oversight of our company’s corporate governance and guidance to our chief executive officer and to set the agenda for and preside over meetings of the Board of Directors.

 

Executive Sessions

 

At each regular meeting of the Board of Directors, our independent directors meet in executive session with no company management present during a portion of the meeting.  Dr. Sullivan as our Chairman of the Board presides over these executive sessions and serves as a liaison between the independent directors and our President and Chief Executive Officer.

 

Board Meetings and Attendance

 

The Board of Directors held seven meetings during 2010.  All of our directors, attended 75 percent or more of the aggregate meetings of the Board of Directors and all committees on which they served during 2010.

 

Board Committees

 

The Board of Directors has three standing committees:  Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee. Each of these committees has the composition and responsibilities described below.  The Board of Directors from time to time may establish other committees to facilitate the management of our company and may change the composition and the responsibilities of our existing committees.  Each committee has a charter which can be found on the Investors—Corporate Governance—Board Committees section of our corporate website at www.biosantepharma.com.

 

17



Table of Contents

 

The table below summarizes the current membership of each of our three standing board committees.

 

Director

 

Audit and
Finance

 

Compensation

 

Nominating and
Corporate Governance

Louis W. Sullivan, M.D.

 

ü

 

Chair

 

ü

Stephen M. Simes

 

 

 

Fred Holubow

 

Chair

 

 

ü

Peter Kjaer

 

 

 

Ross Mangano

 

ü

 

ü

 

ü

John T. Potts, Jr., M.D.

 

 

 

Edward C. Rosenow III, M.D.

 

 

ü

 

Stephen A. Sherwin, M.D.

 

 

ü

 

Chair

 

Audit and Finance Committee

 

Responsibilities.  The primary responsibilities of the Audit and Finance Committee include:

 

·                  overseeing our accounting and financial reporting processes, systems of internal control over financial reporting and disclosure control and procedures on behalf of the Board of Directors and reporting the results or findings of its oversight activities to the Board;

 

·                  having sole authority to appoint, retain and oversee the work of our independent registered public accounting firm and establishing the compensation to be paid to the independent registered public accounting firm;

 

·                  establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls and/or or auditing matters and for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters;

 

·                  reviewing and pre-approving all audit services and permissible non-audit services to be performed for us by our independent registered public accounting firm as provided under the federal securities laws and rules and regulations of the Securities and Exchange Commission; and

 

·                  overseeing our system to monitor and manage risk, and legal and ethical compliance programs, including the establishment and administration (including the grant of any waiver from) a written code of ethics applicable to each of our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

 

The Audit and Finance Committee has the authority to engage the services of outside experts and advisors as it deems necessary or appropriate to carry out its duties and responsibilities.

 

Composition and Audit Committee Financial Expert.  The current members of the Audit and Finance Committee are Messrs. Holubow and Mangano and Dr. Sullivan.  Mr. Kjaer served as a member of the Audit and Finance Committee until March 2010, at which time Mr. Mangano joined the Audit and Finance Committee.  Mr. Holubow is the chair of the Audit and Finance Committee.

 

Each current member of the Audit and Finance Committee qualifies as “independent” for purposes of membership on audit committees pursuant to the Listing Rules of the NASDAQ Stock Market and

 

18



Table of Contents

 

the rules and regulations of the SEC and is “financially literate” as required by the Listing Rules of the NASDAQ Stock Market.  In addition, the Board of Directors has determined that Mr. Holubow qualifies as an “audit committee financial expert” as defined by the rules and regulations of the SEC and meets the qualifications of “financial sophistication” under the Listing Rules of the NASDAQ Stock Market as a result of his Masters in Business Administration in Finance, and his previous experience as an investment analyst and portfolio manager for over 40 years and as a former member of an audit committee of another public company.  Stockholders should understand that these designations related to the Audit and Finance Committee members’ experience and understanding with respect to certain accounting and auditing matters are disclosure requirements of the SEC and the NASDAQ Stock Market and do not impose upon any of them any duties, obligations or liabilities that are greater than those generally imposed on a member of the Audit and Finance Committee or of the Board of Directors.

 

Meetings and Other Information.  The Audit and Finance Committee met four times during 2010.  At all of these meetings, the Audit and Finance Committee met in private session with our independent registered public accounting firm.  Additional information regarding the Audit and Finance Committee and our independent registered public accounting firm is disclosed under the “Audit-Related Matters” and “Proposal No. 3—Ratification of Selection of Independent Registered Public Accounting Firm” sections of this proxy statement.

 

Compensation Committee

 

Responsibilities.  The primary responsibilities of the Compensation Committee include:

 

·                  recommending to the Board of Directors, for its determination, the annual salaries, incentive compensation, long-term incentive compensation, special or supplemental benefits or perquisites and any and all other compensation applicable to our chief executive officer and other executive officers;

 

·                  reviewing and making recommendations to the Board of Directors regarding any revisions to corporate goals and objectives with respect to compensation for our chief executive officer and other executive officers and establishing and leading a process for the full Board of Directors to evaluate the performance of our chief executive officer and other executive officers in light of those goals and objectives;

 

·                  administering our equity-based compensation plans applicable to any employee of our company and recommending to the Board of Directors specific grants of options and other awards for all executive officers and determining specific grants of options and other awards for all other employees, under our equity-based compensation plans; and

 

·                  reviewing and discussing with our President and Chief Executive Officer and reporting periodically to the Board of Directors plans for executive officer development and corporate succession plans for the President and Chief Executive Officer and other key executive officers and employees.

 

The Compensation Committee has the authority to engage the services of outside experts and advisors as it deems necessary or appropriate to carry out its duties and responsibilities.

 

Composition.  The current members of the Compensation Committee are Dr. Sullivan, Mr. Mangano, Dr. Rosenow and Dr. Sherwin.  Dr. Sherwin joined the Compensation Committee in March 2010.

 

19



Table of Contents

 

Dr. Sullivan is the chair of the Compensation Committee.  Each of the four current members of the Compensation Committee is an “independent director” under the Listing Rules of the NASDAQ Stock Market and a “non-employee director” within the meaning of Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

 

Processes and Procedures for Consideration and Determination of Executive Compensation.  As described above under the heading “—Responsibilities,” the Board of Directors has delegated to the Compensation Committee the responsibility, among other things, to make recommendations to the Board of Directors regarding any and all compensation payable to our executive officers, including annual salaries, incentive compensation, long-term incentive compensation and any special or supplemental benefits or perquisites.  The Board of Directors also has delegated to the Compensation Committee the responsibility to administer our equity and incentive compensation plans applicable to any employee of our company and to recommend to the Board of Directors specific grants of options and other awards for all executive officers and determine specific grants of options and other awards for all other employees, under our equity-based compensation plans.  Under the terms of its formal written charter, the Compensation Committee has the power and authority to delegate any of its duties and responsibilities to subcommittees as the Compensation Committee may deem appropriate in its sole discretion.  Historically, the Compensation Committee has not generally delegated any of its duties and responsibilities to subcommittees, but rather has taken such actions as a committee, as a whole.

 

In December 2010, the Board of Directors delegated to the Compensation Committee the authority to determine annual discretionary performance bonuses for our executive officers for 2010, annual base salaries for 2011 and annual stock option grants for 2011.  The Board of Directors decided to delegate these matters since there was a full discussion of such matters at the regular Board meeting in December and it made sense at the time to delegate the final decisions to the Compensation Committee in order to streamline the process.

 

Our President and Chief Executive Officer assists the Compensation Committee in gathering compensation related data regarding our executives, including himself, and making recommendations to the Compensation Committee regarding the form and amount of compensation to be paid to each executive, including himself.  In making final decisions regarding compensation to be paid to our executives, the Compensation Committee and Board of Directors considers the recommendations of our President and Chief Executive Officer recognizing that due to his reporting and otherwise close relationship with employees, the President and Chief Executive Officer is often in a better position than the Compensation Committee and Board of Directors to evaluate the performance of employees (other than himself).  In some cases, the Compensation Committee also considers input from other executives regarding their own compensation.  However, the Compensation Committee recognizes the inherent conflict of interest involved in connection with the recommendations of our President and Chief Executive Officer and other members of management, especially with respect to their own compensation.  Our President and Chief Executive Officer attends most Compensation Committee meetings at the invitation of the Compensation Committee; however, neither our President and Chief Executive Officer nor any other executive officer is present during any discussions, final deliberations and decisions regarding executive officer compensation.

 

The Compensation Committee engaged an independent compensation consultant, BDO Seidman, LLP, to assist the Compensation Committee and the Board of Directors in determining base salaries and option grants for 2010 and an independent compensation consultant, Radford, an Aon Consulting Company, to assist the Compensation Committee and Board of Directors in determining annual bonuses for 2010 and executive compensation for 2011.  Neither BDO Seidman nor Radford provided

 

20



Table of Contents

 

other services to management during the time they provided services to the Compensation Committee.  Radford’s current engagement with the Compensation Committee includes reviewing and advising on all significant aspects of executive compensation.  This includes base salaries, bonuses and equity awards, as well as severance and change in control arrangements.  During 2010, at the request of the Compensation Committee, Radford recommended a peer group of 20 other life-sciences companies, collected relevant market data from these companies to allow the Compensation Committee to compare elements of our compensation program to those of our peers, provided information on executive compensation trends and implications for our company and made other recommendations to the Compensation Committee regarding certain aspects of our executive compensation program.  The Chair of the Compensation Committee, Louis W. Sullivan, M.D., consulted with a representative of either BDO Seidman or Radford prior to most of the Compensation Committee meetings held in 2010.  A representative of BDO Seidman or Radford also was invited to attend several meetings of the Compensation Committee and Board of Directors during 2010.  Both BDO Seidman and Radford were engaged directly by our Compensation Committee and did not advise our management and only worked with management with the express permission of the Compensation Committee.  Neither BDO Seidman nor Radford provided any services to our company other than those for which it was retained by the Compensation Committee.

 

In making final recommendations and decisions regarding compensation to be paid to our executive officers, the Compensation Committee and the Board of Directors consider the recommendations of our President and Chief Executive Officer and the Compensation Committee’s compensation consultant, but also considers other factors, such as its own views as to the form and amount of compensation to be paid, the peer group data provided by the Compensation Committee’s compensation consultant, the general performance of the company and the individual officers and the company’s cash position and anticipated ability to raise any necessary additional financing.  For information on the compensation of our named executive officers, please refer to the “Executive Compensation” section of this proxy statement.

 

Meetings and Other Information.  The Compensation Committee met 11 times during 2010.

 

Nominating and Corporate Governance Committee

 

Responsibilities.  The primary responsibilities of the Nominating and Corporate Governance Committee are:

 

·                  identifying individuals qualified to become Board members;

 

·                  recommending director nominees for each annual meeting of our stockholders and director nominees to fill any vacancies that may occur between meetings of stockholders;

 

·                  being aware of the best practices in corporate governance and developing and recommending to the Board of Directors a set of corporate governance standards to govern the Board of Directors, its committees, the company and its employees in the conduct of the business and affairs of the company;

 

·                  developing and overseeing the annual Board and Board committee evaluation process; and

 

·                  establishing and leading a process for determination of the compensation applicable to the non-employee directors on the Board.

 

21



Table of Contents

 

The Nominating and Corporate Governance Committee has the authority to engage the services of outside experts and advisors as it deems necessary or appropriate to carry out its duties and responsibilities.

 

Processes and Procedures for Consideration and Determination of Director Compensation.  As described in more detail above under the heading “—Responsibilities,” the Board of Directors has delegated to the Nominating and Corporate Governance Committee the responsibility, among other things, to establish and lead a process for determination of compensation payable to our non-employee directors.  The Nominating and Corporate Governance Committee makes recommendations regarding compensation payable to our non-employee directors to the entire Board of Directors, which then makes the final decisions.  Under the terms of its formal written charter, the Nominating and Corporate Governance Committee has the power and authority to delegate any of its duties and responsibilities to subcommittees as the Nominating and Corporate Governance Committee may deem appropriate in its sole discretion.  Historically, the Nominating and Corporate Governance Committee has not generally delegated any of its duties and responsibilities to subcommittees, but rather has taken such actions as a committee, as a whole.

 

At the end of 2010, the Nominating and Corporate Governance Committee engaged Radford, a compensation consulting firm, to conduct a competitive assessment to assist the Nominating and Corporate Governance Committee in formulating its recommendations regarding and the Board of Directors in determining director compensation.  Radford conducted an assessment of the following pay elements: cash compensation, including annual retainers and meeting fees; equity grants, including stock options; and additional compensation paid to Board chairs and Board committee chairs and members.  The assessment was based on the practices of the 20 peer group companies used to evaluate the market competitiveness of our executive compensation program.  We refer you to the information under the heading “Executive Compensation—Summary of Cash and Other Compensation—Use of Peer Group Data” later in this proxy statement for a listing of the 20 peer companies.

 

In making final recommendations and decisions regarding compensation to be paid to our directors, the Nominating and Corporate Governance Committee and the Board of Directors consider the recommendations of Radford, but also other factors, such as its own views as to the form and amount of compensation to be paid, the peer group data provided by Radford, the current and anticipated time demands placed on directors and other factors that may be relevant.

 

In February 2011, the Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, approved certain changes to our director compensation program as described under the heading “Director Compensation—Overview” later in this proxy statement.

 

Composition.  The composition of the Nominating and Corporate Governance Committee changed in December 2010.  The current members of the Nominating and Corporate Governance Committee are Dr. Sullivan, Mr. Holubow, Mr. Mangano and Dr. Sherwin.  Dr. Sherwin is the chair of the Nominating and Corporate Governance Committee.  During most of 2010, Dr. Sullivan, Mr. Holubow, Mr. Kjaer, Mr. Mangano and Mr. Rosenow were members of the Nominating and Corporate Governance Committee and Dr. Sullivan was the chair.  Each of the four current members of the Nominating and Corporate Governance Committee is an “independent director” within the meaning of the Listing Rules of the NASDAQ Stock Market.

 

Meetings and Other Information.  The Nominating and Corporate Governance Committee met three times during 2010.  Additional information regarding the Nominating and Corporate Governance

 

22



Table of Contents

 

Committee is disclosed under the “—Director Nominations Process” and “Director Compensation—Overview” sections of this proxy statement.

 

Director Nominations Process

 

Pursuant to a Director Nominations Process adopted by the Board of Directors, in selecting nominees for the Board of Directors, the Nominating and Corporate Governance Committee first determines whether the incumbent directors are qualified to serve, and wish to continue to serve, on the Board.  The Nominating and Corporate Governance Committee believes that our company and its stockholders benefit from the continued service of qualified incumbent directors because those directors have familiarity with and insight into our company’s affairs that they have accumulated during their tenure with the company.  Appropriate continuity of Board membership also contributes to the Board’s ability to work as a collective body.  Accordingly, it is the practice of the Nominating and Corporate Governance Committee, in general, to re-nominate an incumbent director at the upcoming annual meeting of stockholders if the director wishes to continue his or her service with the Board, the director continues to satisfy the Nominating and Corporate Governance Committee’s criteria for membership on the Board, the Nominating and Corporate Governance Committee believes the director continues to make important contributions to the Board, and there are no special, countervailing considerations against re-nomination of the director.  After completing the Director Nominations Process in early 2011, it was the unanimous recommendation of the Nominating and Corporate Governance Committee that based on his other commitments and priorities Mr. Kjaer not stand for re-election to the Board of Directors at the Annual Meeting.

 

Pursuant to the Director Nominations Process adopted by the Board of Directors, in identifying and evaluating new candidates for election to the Board, the Nominating and Corporate Governance Committee intends to first solicit recommendations for nominees from persons whom the Nominating and Corporate Governance Committee believes are likely to be familiar qualified candidates having the qualifications, skills and characteristics required for Board nominees from time to time.  Such persons may include members of the Board of Directors and senior management of BioSante.  In addition, the Nominating and Corporate Governance Committee may engage a search firm to assist it in identifying qualified candidates.  The Nominating and Corporate Governance Committee then intends to review and evaluate each candidate whom it believes merits serious consideration, taking into account available information concerning the candidate, any qualifications or criteria for Board membership established by the Nominating and Corporate Governance Committee, the existing composition of the Board, and other factors that it deems relevant.  In conducting its review and evaluation, the Nominating and Corporate Governance Committee may solicit the views of our management, other Board members, and any other individuals it believes may have insight into a candidate.  The Nominating and Corporate Governance Committee may designate one or more of its members and/or other Board members to interview any proposed candidate.

 

The Nominating and Corporate Governance Committee will consider recommendations for the nomination of directors submitted by our stockholders.  For more information, see the information set forth under the heading “Other Matters — Director Nominations for 2011 Annual Meeting.”  The Nominating and Corporate Governance Committee will evaluate candidates recommended by stockholders in the same manner as those recommended as stated above.

 

There are no formal requirements or minimum qualifications that a candidate must meet in order for the Nominating and Corporate Governance Committee to recommend the candidate to the Board of Directors.  The Nominating and Corporate Governance Committee believes that each nominee should be evaluated based on his or her merits as an individual, taking into account the needs of our company

 

23



Table of Contents

 

and the Board of Directors.  However, in evaluating candidates, there are a number of criteria that the Nominating and Corporate Governance Committee generally views as relevant and is likely to consider.  Some of these factors include:

 

·                  whether the candidate is an “independent director” under the Listing Rules of the NASDAQ Stock Market and meets any other applicable independence tests under the federal securities laws and rules and regulations of the SEC;

 

·                  whether the candidate is “financially sophisticated” and otherwise meets the requirements for serving as a member of an audit committee under the Listing Rules of the NASDAQ Stock Market;

 

·                  whether the candidate is an “audit committee financial expert” under the rules and regulations of the SEC;

 

·                  the needs of our company with respect to the particular talents and experience of our directors;

 

·                  the personal and professional integrity and reputation of the candidate;

 

·                  the candidate’s level of education and business experience;

 

·                  the candidate’s broad-based business acumen;

 

·                  the candidate’s level of understanding of our business and its industry and other industries relevant to our business;

 

·                  the candidate’s ability and willingness to devote adequate time to work of the Board of Directors and its committees;

 

·                  the fit of the candidate’s skills and personality with those of other directors and potential directors in building a board of directors that is effective, collegial and responsive to the needs of our company;

 

·                  whether the candidate possesses strategic thinking and a willingness to share ideas;

 

·                  the candidate’s diversity of experiences, expertise and background; and

 

·                  the candidate’s ability to represent the interests of all stockholders and not a particular interest group.

 

While we do not have a stand-alone diversity policy, in considering whether to recommend any director nominee, including candidates recommended by stockholders, the Nominating and Corporate Governance Committee will consider the factors above, including the candidate’s diversity of experiences, expertise and background.  The Nominating and Corporate Governance Committee seeks nominees with a broad diversity of experience, expertise and backgrounds.  The Nominating and Corporate Governance Committee does not assign specific weights to particular criteria and no particular criterion is necessarily applicable to all prospective nominees.  We believe that the backgrounds and qualifications of the directors, considered as a group, should provide a significant

 

24



Table of Contents

 

mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities.

 

Board Oversight of Risk

 

The Board of Directors as a whole has responsibility for risk oversight, with more in-depth reviews of certain areas of risk being conducted by the relevant Board committees that report on their deliberations to the full Board of Directors.  The oversight responsibility of the Board and its committees is enabled by management reporting processes that are designed to provide information to the Board about the identification, assessment and management of critical risks and management’s risk mitigation strategies.  The areas of risk that we focus on include regulatory, operational, financial (accounting, credit, liquidity and tax), legal, compensation, competitive, health, safety and environment, economic, political and reputational risks.

 

The standing committees of the Board of Directors oversee risks associated with their respective principal areas of focus.  The Audit and Finance Committee’s role includes a particular focus on the qualitative aspects of financial reporting to stockholders, on our processes for the management of business and financial risk, our financial reporting obligations and for compliance with significant applicable legal, ethical and regulatory requirements.  The Audit and Finance Committee, along with management, is also responsible for developing and participating in a process for review of important financial and operating topics that present potential significant risk to our company.  The Compensation Committee is responsible for overseeing risks and exposures associated with our compensation programs and arrangements, including our executive and director compensation programs and arrangements, and management succession planning.  The Nominating and Corporate Governance Committee oversees risks relating to our corporate governance matters and policies and director succession planning.

 

We recognize that a fundamental part of risk management is understanding not only the risks a company faces and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate for the company.  The involvement of the full Board of Directors in setting our business strategy is a key part of the Board’s assessment of management’s appetite for risk and also a determination of what constitutes an appropriate level of risk for our company.

 

We believe our current Board leadership structure is appropriate and helps ensure proper risk oversight for our company for a number of reasons, including: (1) general risk oversight by the full Board of Directors in connection with its role in reviewing our key long-term and short-term business strategies and monitoring on an on-going basis the implementation of our key business strategies; (2) more detailed oversight by our standing Board committees that are currently comprised of and chaired by our independent directors, and (3) the focus of our Chairman of the Board on allocating appropriate Board agenda time for discussion regarding the implementation of our key business strategies and specifically risk management.

 

Code of Conduct and Ethics

 

Our Code of Conduct and Ethics applies to all of our directors, executive officers, including our President and Chief Executive Officer and our Chief Financial Officer, and other employees, and meets the requirements of the SEC.  A copy of our Code of Conduct and Ethics is available on the Investors—Corporate Governance—Code of Conduct and Ethics section of our corporate website at www.biosantepharma.com.

 

25



Table of Contents

 

Policy Regarding Director Attendance at Annual Meetings of Stockholders

 

It is the policy of the Board of Directors that directors standing for re-election should attend our annual meeting of stockholders, if their schedules permit.  All of the directors attended our annual meeting of stockholders in June 2010, except Dr. Potts.

 

Complaint Procedures

 

The Audit and Finance Committee has established procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls, or auditing matters, and the submission by our employees, on a confidential and anonymous basis, of concerns regarding questionable accounting or auditing matters.  Our personnel with such concerns are encouraged to discuss their concerns with their supervisor first, who in turn will be responsible for informing our Compliance Officer of any concerns raised.  Our President and Chief Executive Officer, Stephen M. Simes, currently serves as our Compliance Officer.  If an employee prefers not to discuss a particular matter with his or her own supervisor, the employee may instead discuss such matter with our Compliance Officer.  If an individual prefers not to discuss a matter with the Compliance Officer or if the Compliance Officer is unavailable and the matter is urgent, the individual is encouraged to contact the Chairman of the Audit and Finance Committee, Mr. Fred Holubow.

 

Process Regarding Stockholder Communications with Board of Directors

 

Stockholders may communicate with the Board of Directors or any one particular director by sending correspondence, addressed to our Corporate Secretary, BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Suite 400, Lincolnshire, IL 60069, with an instruction to forward the communication to the Board of Directors or one or more particular directors.  Our Corporate Secretary will forward promptly all such stockholder communications to the Board of Directors or the one or more particular directors, with the exception of any advertisements, solicitations for periodical or other subscriptions and other similar communications.

 

26



Table of Contents

 

DIRECTOR COMPENSATION

 


 

Summary of Cash and Other Compensation

 

The table below provides summary information concerning the compensation of each individual who served as a director of our company during the year ended December 31, 2010, other than Stephen M. Simes, our Vice Chairman, President and Chief Executive Officer, whose compensation is set forth under the heading “Executive Compensation.”

 

DIRECTOR COMPENSATION - 2010

 

Name

 

Fees Earned or
Paid in Cash ($)

 

Option
Awards ($)(1)(2)

 

All Other
Compensation ($)(3)

 

Total ($)

 

Louis W. Sullivan, M.D.

 

$

76,500

 

$

18,154

 

$

0

 

$

94,654

 

Fred Holubow

 

45,900

 

12,103

 

0

 

58,003

 

Peter Kjaer

 

30,600

 

12,103

 

0

 

42,703

 

Ross Mangano

 

45,000

 

12,103

 

0

 

57,103

 

John T. Potts, Jr., M.D.

 

27,900

 

12,103

 

0

 

40,003

 

Edward C. Rosenow III, M.D.

 

39,600

 

12,103

 

0

 

51,703

 

Stephen A. Sherwin, M.D.

 

36,000

 

12,103

 

0

 

48,103

 

 


(1)        On March 31, 2010, each of our non-employee directors received an option to purchase 10,000 shares of our common stock at an exercise price of $1.79 per share granted under the BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan, the material terms of which are described in more detail under the heading “Executive Compensation — Grants of Plan-Based Awards — BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan.”  In addition, Dr. Sullivan, as Chairman of the Board, received an option to purchase an additional 5,000 shares of our common stock.  Such options expire on March 30, 2020 and vested in full on March 31, 2011.  Amounts reported in the “Option Awards” column represent the aggregate grant date fair value for option awards granted to each director in 2010 computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718.  The grant date fair value is determined based on our Black-Scholes option pricing model.  The grant date fair value per share for the options granted on March 31, 2010 was $1.21 and was determined using the following specific assumptions:  risk free interest rate:  2.89%; expected life:  6 years; expected volatility:  75.72%; and expected dividend yield:  0%.

 

(2)        The following table provides information regarding the aggregate number of options to purchase shares of our common stock outstanding at December 31, 2010 and held by each of the directors listed in the table:

 

Name

 

Aggregate Number
of Securities
Underlying Options

 

Exercisable/
Unexercisable

 

Range of
Exercise
Price(s)

 

Range of
Expiration
Date(s)

 

Louis W. Sullivan, M.D.

 

130,000

 

115,000/15,000

 

$1.51 – 4.405

 

03/15/2016 – 03/30/2020

 

Fred Holubow

 

120,000

 

110,000/10,000

 

1.51 – 4.405

 

03/15/2016 – 03/30/2020

 

Peter Kjaer

 

120,000

 

110,000/10,000

 

1.51 – 4.405

 

03/15/2016 – 03/30/2020

 

Ross Mangano

 

120,000

 

110,000/10,000

 

1.51 – 4.405

 

03/15/2016 – 03/30/2020

 

John T. Potts, Jr., M.D.

 

25,000

 

3,750/21,250

 

1.79 – 1.82

 

10/13/2019 – 03/30/2020

 

Edward C. Rosenow III, M.D.

 

120,000

 

110,000/10,000

 

1.51 – 4.405

 

03/15/2016 – 03/30/2020

 

Stephen A. Sherwin, M.D.(a)

 

143,359

 

122,109/21,250

 

1.79 – 36.82

 

02/03/2015 – 03/30/2020

 

 


(a)        Of the total number of options held by Dr. Sherwin, options to purchase an aggregate of 118,359 shares of our common stock at a weighted average exercise price of $17.90 were granted under equity-based compensation plans of Cell Genesys, Inc. and assumed by us in our October 2009 merger with Cell Genesys.

 

(3)        We do not provide perquisites or other personal benefits to our directors.

 

27



Table of Contents

 

Overview of Director Compensation Program

 

As described in more detail under the heading “Corporate Governance—Nominating and Corporate Governance Committee—Responsibilities,” the Board of Directors has delegated to the Nominating and Corporate Governance Committee the responsibility, among other things, to establish and lead a process for the determination of compensation payable to our non-employee directors.  The Nominating and Corporate Governance Committee makes recommendations regarding compensation payable to our non-employee directors to the entire Board of Directors, which then makes final decisions regarding such compensation.  The processes and procedures the Nominating and Corporate Governance Committee and the Board of Directors use to consider and determine director compensation are described under the heading “Corporate Governance— Nominating and Corporate Governance Committee—Processes and Procedures for Determination of Director Compensation.”

 

The principal elements of our director compensation program for 2010 included:

 

·                  annual cash retainers;

 

·                  meeting fees; and

 

·                  long-term equity-based incentive compensation, in the form of stock options.

 

We do not compensate Mr. Simes separately for serving on the Board of Directors.  We do, however, reimburse each member of the Board of Directors, including Mr. Simes, for out-of-pocket expenses incurred in connection with attending Board and Board committee meetings.

 

Recent Changes to Director Compensation Program

 

The Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, reviewed our director compensation program and made several changes to the program in February 2011.

 

As described in more detail under the heading “Corporate Governance— Nominating and Corporate Governance Committee—Processes and Procedures for Determination of Director Compensation,” the Nominating and Corporate Governance Committee engaged Radford, a compensation consulting firm, at the end of 2010 to conduct a competitive assessment of director compensation of companies in our industry sector to assist the Nominating and Corporate Governance Committee in reviewing our director compensation program.  Our industry sector is defined as a peer group of 20 other publicly-held life science companies in late stage clinical development and/or the FDA approval process, with market capitalizations, revenues and organization sizes similar to ours. Almost all of the members of our peer group at the time our peer group was created had a market capitalization between $50 million and $450 million, revenue of less than $125 million and an organization size of under 300 employees.  We use the same peer group for purposes of analyzing our executive compensation.  We refer you to the information under the heading “Executive Compensation—Overview—Use of Peer Group Data” for the names of the companies in our peer group and for additional information regarding the peer group.

 

Radford conducted an assessment of the following director pay elements: cash compensation, including annual retainers and meeting fees; equity grants, including stock options; and additional Board and Board committee chair and member compensation. In determining director compensation,

 

28



Table of Contents

 

the Nominating and Corporate Governance Committee targets total compensation and each element of compensation at the 50th percentile of our peer group.  According to the findings of Radford:

 

·                  our average total direct compensation for our non-employee directors was below the peer 50th percentile;

 

·                  our baseline Board member cash compensation, which similar to 55 percent of our peer companies, consists of an annual Board retainer plus Board meeting fees, was below the peer 50th percentile;

 

·                  additional cash provided to our Board committee chairs and members was below the peer 50th percentile; and

 

·                  our initial and annual equity grants were below the peer 50th percentile in long-term incentive value delivered and in total shares granted as a percent of company.

 

The changes to our director compensation approved by the Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, in February 2011 are described below.  As a result of the changes to our director compensation,

 

·                  our average total direct compensation for our non-employee directors is still below the peer 50th percentile;

 

·                  our baseline Board member cash compensation, which consists of an annual Board retainer plus Board meeting fees, is slightly below the peer 50th percentile;

 

·                  additional cash provided to our Board committee chairs and members is either between the peer 50th percentile and peer 75th percentile, or in some cases, above the peer 75th percentile; and

 

·                  our initial and annual equity grants are below the peer 50th percentile in terms of long-term incentive value delivered but between the peer 50th percentile and 75th percentile in terms of total shares granted as a percent of company.

 

Both the Board of Directors and Nominating and Corporate Governance Committee recognize that the additional cash provided to our Board committee chairs and members is above the targeted peer 50th percentile and that our initial and annual equity grants while below the peer 50th percentile in terms of long-term incentive value delivered are between the peer 50th percentile and 75th percentile in terms of total shares granted as a percent of company.  In approving such components, the Board of Directors and Nominating and Corporate Governance Committee considered:

 

·                  the fact that our average total direct compensation per director and certain other components of our revised director compensation program are still below the peer 50th percentile;

 

·                  the increasing amount of workload delegated to and performed by our Board committee chairs and members;

 

·                  the intent that our revised director compensation program apply during both 2011 and 2012; and

 

29



Table of Contents

 

·                  the peer market data is based on 2009 peer group practices, and according to Radford, a number of our peer companies have increased their director compensation since 2009, which means that our revised director compensation likely will be at the 50th percentile in the near future in light of such increases.

 

Cash Compensation

 

The cash compensation paid to our non-employee directors consists of annual Board and Board committee cash retainers and meeting fees.

 

The table below sets forth the annual cash retainers paid to our non-employee directors during 2010 and the annual cash retainers to be paid during 2011 effective February 23, 2011:

 

Description

 

2010 Annual
Cash Retainer

 

2011 Annual
Cash Retainer

 

Board Member

 

$

18,000

 

$

25,000

 

Chairman of the Board (in addition to Board member retainer)

 

22,500

 

12,500

 

Audit and Finance Committee Chair

 

9,000

 

15,000

 

Compensation Committee Chair

 

4,500

 

10,000

 

Nominating and Corporate Governance Committee Chair

 

4,500

 

7,000

 

Audit and Finance Committee Member (other than Chair)

 

0

 

7,500

 

Compensation Committee Member (other than Chair)

 

0

 

5,000

 

Nominating and Corporate Governance Committee Member (other than Chair)

 

0

 

3,500

 

 

The annual cash retainers are paid on a quarterly basis in the beginning of each calendar quarter.  For example, the retainers paid in the beginning of the first calendar quarter are for the period from January 1 through March 31.

 

The table below sets forth the per meeting fees paid to our non-employee directors during 2010 and the per meeting fees to be paid during 2011 effective February 23, 2011:

 

Description

 

2010
Meeting Fees

 

2011
Meeting Fees

 

Board Meeting (in person)

 

$

1,800

 

$

2,000

 

Board Meeting (telephonic)

 

900

 

1,000

 

Board Committee (in person or telephonic)

 

900

 

1,000

 

 

30



Table of Contents

 

Stock Options

 

Each of our non-employee directors receives an automatic grant of options to purchase shares of our common stock upon the director’s initial election to the Board of Directors and on an annual basis on the last business day of March each year.  In addition, our Chairman of the Board receives an additional automatic option grant.  The options have a ten-year term and an exercise price equal to the fair market value of our common stock on the grant date.  The initial options vest and become exercisable in four equal annual installments and the annual options vest and become exercisable in full on the one-year anniversary of the grant date.  The table below sets forth the number of options granted to each of our non-employee directors as initial and annual grants during 2010 and 2011 and the additional option grant to our Chairman of the Board:

 

Description

 

Number of Shares Underlying
2010 Option Grants

 

Number of Shares Underlying
2011 Option Grants

 

New Board Member (initial grant)

 

15,000

 

50,000

 

Board Member (annual basis)

 

10,000

 

25,000

 

Chairman of the Board (annual basis)

 

5,000

 

10,000

 

 

We refer you to note 1 to the Director Compensation table above for a summary of all options granted to our directors, excluding Mr. Simes, during the year ended December 31, 2010.  We refer you to note 2 to the Director Compensation table above for a summary of all options to purchase shares of our common stock held by our directors, excluding Mr. Simes, as of December 31, 2010.  Information regarding stock option grants to Mr. Simes during the year ended December 31, 2010 is set forth under the heading “Executive Compensation—Grants of Plan-Based Awards” and information regarding all stock options held by Mr. Simes as of December 31, 2010 is set forth under the heading “Executive Compensation—Outstanding Equity Awards at Fiscal Year End.”

 

Under the terms of our stock option agreements, upon a director’s termination of service with our company, other than for cause, such director’s vested and outstanding options as of such date remain vested and outstanding for a period of three months and all non-vested options terminate.  Depending upon the circumstances of a director’s separation of service with our company, however, we may change these terms, although any adverse change would require the consent of the director.  In February 2011, the Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, approved an amendment to Mr. Kjaer’s outstanding stock options effective as of his last day of service as a director of our company to extend his post-separation of service exercise period from three months to one year (but no later than the original expiration date of the options).  The Board of Directors decided to extend the exercise period of Mr. Kjaer’s stock options in light of his over 10 years of service as a member of our Board of Directors.

 

Indemnification Agreements

 

We have entered into agreements with all of our directors under which we are required to indemnify them against expenses, judgments, penalties, fines, settlements and other amounts actually and reasonably incurred, including expenses of a derivative action, in connection with an actual or threatened proceeding if any of them may be made a party because he or she is or was one of our directors.  We will be obligated to pay these amounts only if the director acted in good faith and in a manner that he or she reasonably believed to be in or not opposed to our best interests.  With respect to any criminal proceeding, we will be obligated to pay these amounts only if the director had no reasonable cause to believe his or her conduct was unlawful.  The indemnification agreements also set forth procedures that will apply in the event of a claim for indemnification.

 

31



Table of Contents

 

EXECUTIVE COMPENSATION

 


 

Summary of Cash and Other Compensation

 

The table below provides summary information concerning all compensation awarded to, earned by or paid to our principal executive officer and our principal financial officer during the years ended December 31, 2010, 2009 and 2008 and our only other executive officer during the year ended December 31, 2010.  We did not have any other executive officers as of December 31, 2010.  We refer to the three individuals named in the table below as our “named executive officers” or our “executives” in this proxy statement.

 

SUMMARY COMPENSATION TABLE - 2010

 

 

 

 

 

 

 

 

 

Option

 

All Other

 

 

 

Name and Principal Position

 

Year

 

Salary(1)

 

Bonus(2)

 

Awards(3)

 

Compensation(4)

 

Total

 

Stephen M. Simes

 

2010

 

$

486,231

 

$

270,900

 

$

156,000

 

$

36,248

 

$

949,379

 

Vice Chairman, President and Chief Executive Officer

 

2009

 

417,640

 

275,000

 

300,000

 

37,162

 

1,038,802

 

 

2008

 

417,640

 

0

 

249,000

 

30,879

 

697,519

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Phillip B. Donenberg

 

2010

 

285,552

 

112,000

 

104,000

 

28,663

 

530,215

 

Senior Vice President of Finance, Chief Financial Officer and Secretary

 

2009

 

232,140

 

175,000

 

128,750

 

21,507

 

557,397

 

 

2008

 

232,140

 

0

 

149,400

 

20,123

 

401,663

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Michael C. Snabes, M.D., Ph.D.(5)

 

2010

 

374,487

 

109,500

 

26,000

 

18,200

 

528,187

 

Senior Vice President of Medical Affairs

 

 

 

 

 

 

 

 

 

 

 

 

 

 


(1)          For 2010, includes $34,731, $19,885 and $26,154 paid to Mr. Simes, Mr. Donenberg and Dr. Snabes, respectively, for unused accrued vacation time.  We refer you to the information under the heading “— Payout of Certain Accrued Vacation Balances” for more information regarding these payments.  In addition, we refer you to the information under the heading “— Base Salaries” for a discussion of the factors taken into consideration by the Board of Directors in determining the base salaries for each executive.

 

(2)          Represents discretionary performance cash bonuses earned in year as indicated, but in the case of some years, paid during the following year.  We refer you to the information under the heading “— Annual Discretionary Performance Bonus” for a discussion of the factors taken into consideration by the Board of Directors in determining the amount of discretionary annual cash bonus paid to each executive.

 

(3)          Amounts reported in the “Option Awards” column represent the aggregate grant date fair value for option awards granted to each named executive officer during each of the years presented, as computed in accordance with FASB ASC Topic 718.  The grant date fair value is determined based on our Black-Scholes option pricing model.  The following table sets forth the specific assumptions used in the valuation of each such option award:

 

Grant
Date

 

Grant Date Fair
Value Per Share

 

Risk Free
Interest Rate

 

Expected
Life

 

Expected
Volatility

 

Expected
Dividend Yield

 

02/02/10

 

$

1.04

 

2.37%

 

6 years

 

76.87%

 

0%

 

02/02/09

 

1.03

 

2.76%

 

6 years

 

76.83%

 

0%

 

01/15/08

 

2.49

 

3.72%

 

6 years

 

67.51%

 

0%

 

 

(4)          The amounts shown in the “All Other Compensation” column for 2010 include the following with respect to each named executive officer:

 

Name

 

401(k)
Match
(a)

 

Insurance
Premiums
(b)

 

Tax
Gross-Up
(c)

 

Auto
Allowance

 

Stephen M. Simes

 

$

11,000

 

$

9,178

 

$

4,070

 

$

12,000

 

Phillip B. Donenberg

 

11,000

 

8,056

 

2,407

 

7,200

 

 

32



Table of Contents

 

Name

 

401(k)
Match
(a)

 

Insurance
Premiums
(b)

 

Tax
Gross-Up
(c)

 

Auto
Allowance

 

Michael C. Snabes, M.D., Ph.D.

 

11,000

 

0

 

0

 

7,200

 

 


(a)          Based on 50 percent of the amount the named executive officer voluntarily contributed to the plan.

 

(b)         Includes reimbursement for premiums paid by the named executive officer for long-term disability insurance and for supplemental term life insurance.

 

(c)          Based on the named executive officer’s tax rate at the time the premium was paid.

 

(5)          Dr. Snabes was promoted to an executive officer in August 2010 and was not a named executive officer in 2009 or 2008; and therefore, information on his compensation for those fiscal years is not included.

 

Compensation Philosophy and Target Positioning.  During 2010, the Compensation Committee approved an executive compensation philosophy and target positioning.  Our executive compensation program is designed to:

 

·                  Attract and retain executives important to the success of our company and the creation of value for our stockholders;

 

·                  Motivate our executives to achieve company and individual performance objectives and create stockholder value; and

 

·                  Reward our executives for the achievement of company and individual performance objectives, the creation of stockholder value in the short and long term and their contributions, in general, to the success of our company.

 

In order to achieve these objectives, the Compensation Committee targets base compensation and total compensation at the 50th percentile of companies in our peer group.  The Compensation Committee believes that median positioning attracts and retains executive talent, but at the same time recognizes our company’s cost structure, especially with respect to fixed base compensation. The actual target compensation for each individual executive may be higher or lower than the targeted market position based on the individual’s skills, experience, contribution, performance, tenure or other factors that the Compensation Committee may take into account that are relevant to the individual executive.

 

Use of Peer Group Data.  During 2010, the Compensation Committee engaged Radford to conduct an executive compensation competitive assessment of the base salaries, annual bonus opportunity, total cash compensation, stock options and total direct compensation paid to our executive officers in comparison to similar executives of other companies in our peer group.  The Compensation Committee used this information to assist it in determining the amount of base salary, annual incentive compensation, total compensation and the form and amount of long-term equity-based incentive compensation to pay our executives.

 

During 2010, the Compensation Committee worked with Radford to define a peer group of 20 other publicly-held life science companies in late stage clinical development and the FDA approval process, with market capitalizations, revenues and organization sizes similar to ours. Almost all of the members of our peer group at the time the peer group was created had a market capitalization between $50 million and $450 million, revenue of less than $125 million and an organization size of under 300 employees. We use the same peer group for purposes of analyzing our director compensation.

 

33



Table of Contents

 

The companies in our peer group include:

 

Alexza Pharmaceuticals, Inc.

Antares Pharma, Inc.

Cornerstone Therapeutics Inc.

Curis, Inc.

Cytokinetics, Incorporated

CytRx Corporation

Dyax Corp.

GTx, Inc.

Idenix Pharmaceuticals, Inc.

Inspire Pharmaceuticals, Inc.

Ista Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Ligand Pharmaceuticals Incorporated

NPS Pharmaceuticals, Inc.

Omeros Corporation

OncoGenex Pharmaceuticals, Inc.

Oncothyreon Inc.

Pozen Inc.

Progenics Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc.

 

 

In reviewing benchmarking data, the Compensation Committee recognizes that benchmarking may not always be appropriate as a stand-alone tool for setting compensation due to the aspects of our business and objectives that may be unique to our company.  Nevertheless, the Compensation Committee believes that gathering this information is an important part of its compensation-related decision-making process.  The Compensation Committee believes that compensation paid by peer group companies is representative of the compensation required to attract, retain and motivate our executive talent.  However, where a sufficient basis for comparison does not exist between the peer group data and an executive, the Compensation Committee gives less weight to the peer group data.  For example, relative compensation benchmarking analysis does not consider individual specific performance or experience.

 

Executive Compensation Components.  The principal elements of our executive compensation program for 2010 were:

 

·                  base salary;

 

·                  short-term cash incentive compensation, in the form of an annual discretionary performance cash bonus;

 

·                  long-term equity-based incentive compensation, in the form of stock options; and

 

·                  other compensation arrangements, such as benefits made generally available to our other employees, limited executive benefits and perquisites, and severance and change in control arrangements.

 

In determining the form of compensation to pay our named executive officers, the Compensation Committee views these elements of our executive compensation program as related but distinct.  The Compensation Committee does not believe that significant compensation derived by an executive from one element of our compensation program should necessarily result in a reduction in the amount of compensation the executive receives from other elements. At the same time, the Compensation Committee does not believe that minimal compensation derived from one element of compensation should result necessarily in an increase in the amount the executive should receive from one or more other elements of compensation.

 

Except as described below, the Compensation Committee has not adopted any formal or informal policies or guidelines for allocating compensation between long-term and currently paid out compensation, between cash and non-cash compensation, or among different forms of non-cash compensation.  However, the Compensation Committee’s philosophy is to make a greater percentage of an executive’s compensation performance-based, and therefore at risk, as the executive’s position and responsibility increases given the influence more senior level executives generally have on

 

34



Table of Contents

 

company performance.  Thus, individuals with greater roles and responsibilities associated with achieving our company’s objectives should bear a greater proportion of the risk that those goals are not achieved and should receive a greater proportion of the reward if objectives are met or surpassed. For example, this philosophy is illustrated by the higher cash incentive targets and equity-based awards of our President and Chief Executive Officer as compared to our other two executives.

 

Total Compensation Mix and Pay for Performance.  The table below illustrates how total compensation for our named executive officers for 2010 was allocated between performance and non-performance based components, how performance based compensation is allocated between short-term and long-term components and how total compensation is allocated between cash-based and equity-based components.

 

 

 

Total Compensation Mix
(base salary, short-term cash incentives, long-term
equity incentives and executive benefits and perquisites)

 

 

 

Percent of Total
Compensation that is:

 

Percent of Performance
Based Total Compensation
that is:

 

Percent of Total
Compensation that is:

 

 

 

Performance
Based(1)

 

Fixed(2)

 

Annual(3)

 

Long-Term(4)

 

Cash Based(5)

 

Equity
Based(6)

 

Stephen M. Simes

 

45.0%

 

55.0%

 

63.5%

 

36.5%

 

83.6%

 

16.4%

 

Phillip B. Donenberg

 

40.7%

 

59.3%

 

51.9%

 

48.1%

 

80.4%

 

19.6%

 

Michael C. Snabes, M.D., Ph.D.

 

25.7%

 

74.3%

 

80.8%

 

19.2%

 

95.1%

 

4.9%

 

 


(1)         Short-term cash incentives plus long-term equity incentives divided by total compensation

(2)         Base salary plus executive benefits and perquisites divided by total compensation

(3)         Short-term cash incentives divided by short-term cash incentives plus long-term equity incentives

(4)         Long-term equity incentives divided by short-term cash incentives plus long-term equity incentives

(5)         Base salary plus short-term cash incentives and executive benefits and perquisites divided by total compensation

(6)         Long-term equity incentives divided by total compensation

 

To align the interests of our named executive officers with the interests of our stockholders, a significant part of the total compensation paid to our named executive officers, was performance-based, and a significant part of the performance-based compensation was in the form of long-term equity incentives.  It is the intent of the Compensation Committee to increase the percentage of total compensation paid to our named executive officers that is equity-based in order to further align the interests of our named executive officers with the interests of our stockholders.  In furtherance of this objective, as described in more detail later in this proxy statement, the Compensation Committee granted significant option grants to our named executive officers in January 2011.  Such option grants, however, are subject to a longer four-year vesting as opposed to the typical three-year vesting of prior executive grants.

 

Simes Employment Letter Agreement.  In January 1998, we entered into an employment letter agreement with Stephen M. Simes.  We amended the agreement in July 2008 to ensure compliance with regulations on non-qualified deferred compensation severance benefits as mandated by Section 409A of the Internal Revenue Code of 1986 and to make certain changes to the change in control provisions.  We have not amended the agreement since July 2008.  The current term of the agreement continues until December 31, 2013.  On January 1 of each year, the term is automatically extended for an additional one year unless on or before October 1 immediately preceding the extension, either party gives written notice to the other of the termination of the agreement or cessation of further

 

35



Table of Contents

 

extensions.  Under the agreement, Mr. Simes is entitled to a base salary in an amount determined by the Board of Directors, which base salary, however, must be adjusted upward each year at a minimum equal to changes in the Consumer Price Index.  Mr. Simes is entitled to receive an annual discretionary performance bonus, the amount and terms of which will be determined in the discretion of the Board of Directors.  Mr. Simes also is entitled to a monthly stipend of $1,000 for automobile use, reimbursement of premiums for supplemental term life and long-term disability insurance and taxes associated with such premiums and four weeks paid vacation each year.  If Mr. Simes is terminated without cause or upon a change in control or if he terminates his employment for good reason, he will be entitled to certain payments and benefits as described in more detail under the heading “—Potential Payments Upon Termination or Change in Control.”  Under the agreement, Mr. Simes is subject to customary assignment of inventions, confidentiality and non-competition provisions.

 

Donenberg Employment Letter Agreement.  In June 1998, we entered into an employment letter agreement with Phillip B. Donenberg.  We amended the agreement in July 2008 to ensure compliance with regulations on non-qualified deferred compensation severance benefits as mandated by Section 409A of the Internal Revenue Code of 1986 and to make certain changes to the change in control provisions.  We have not amended the agreement since July 2008.  The term of the agreement continues until either party gives 30 days written notice to the other of the termination of the agreement.  Under the agreement, Mr. Donenberg is entitled to a base salary in an amount determined by the Board of Directors, which base salary, however, must be adjusted upward each year at a minimum equal to changes in the Consumer Price Index.  Mr. Donenberg is entitled to receive an annual discretionary performance bonus, the amount and terms of which will be determined in the discretion of the Board of Directors.  Mr. Donenberg also is entitled to a monthly stipend of $600 for automobile use, reimbursement of premiums for supplemental term life and long-term disability insurance and taxes associated with such premiums and four weeks paid vacation each year.  If Mr. Donenberg is terminated without cause or upon a change in control or if he terminates his employment for good reason, he will be entitled to certain payments and benefits as described in more detail under the heading “—Potential Payments Upon Termination or Change in Control.”  Under the agreement, Mr. Donenberg is subject to customary assignment of inventions, confidentiality and non-competition provisions.

 

Snabes Offer Letter and Change of Control and Severance Agreement.  In April 2008, we entered into an offer letter agreement with Michael C. Snabes, M.D., Ph.D.  Dr. Snabes is employed at-will and is not guaranteed employment for any specified duration.  The offer letter does not contain any commitments regarding future salary increases or benefits, except for the timing of payments and a general description of benefits.  Dr. Snabes is entitled to receive an annual discretionary performance bonus of up to 30 percent of his then base salary, the amount and terms of which will be determined in the discretion of the Board of Directors.  Dr. Snabes also is entitled to a monthly stipend of $600 for automobile use, reimbursement for reasonable monthly cell phone charges and 15 days paid vacation each year.  Under a separate change of control and severance agreement, if Dr. Snabes is terminated without cause or upon a change in control, he will be entitled to certain payments and benefits as described in more detail under the heading “—Potential Payments Upon Termination or Change in Control.”  Dr. Snabes is subject to customary assignment of inventions, confidentiality and non-competition obligations.

 

Base Salaries.  We provide a base salary for our named executive officers, which, unlike some of the other elements of our executive compensation program, is not subject to company or individual performance risk.  We recognize the need for most executives to receive at least a portion of their

 

36



Table of Contents

 

total compensation in the form of a guaranteed base salary that is paid in cash semi-monthly throughout the year.  We initially fix base salaries for our executives at a level we believe enables us to hire and retain them in a competitive environment and to reward satisfactory individual performance and a satisfactory level of contribution to our overall business objectives.  We typically increase the base salaries of our named executive officers in the beginning of each year in an amount equal to an approximate cost of living adjustment.  We do so to recognize annual increases in the cost of living and to ensure that our base salaries remain market competitive.  In addition, we may make additional upward adjustments to a particular executive’s base salary to compensate an executive for assuming increased roles and responsibilities, to reward an executive for superior individual performance, to retain an executive at risk of recruitment by other companies, and/or to bring an executive’s base salary closer to the 50th percentile of companies in our peer group.

 

The table below shows the base salaries for our named executive officers as of January 1 of each of 2009, 2010 and 2011 and the percentage increases between periods:

 

 

 

January 1,

 

Percent

 

January 1,

 

Percent

 

 

 

2009

 

2010

 

Change

 

2010

 

2011

 

Change

 

Stephen M. Simes

 

$

417,640

 

$

451,500

 

8.1%

 

$

451,500

 

$

496,700

 

10.0%

 

Phillip B. Donenberg

 

232,140

 

258,000

 

11.1%

 

258,000

 

308,000

 

19.4%

 

Michael C. Snabes, M.D., Ph.D.

 

315,000

 

340,000

 

7.9%

 

340,000

 

376,000

 

10.6%

 

 

Both Mr. Donenberg and Dr. Snabes received promotions to Senior Vice President and related increases in their base salaries effective September 1, 2010.  Mr. Donenberg’s salary increased 8.5 percent from $258,000 to $280,000 and Dr. Snabes’s base salary increased 7.4 percent from $340,000 to $365,000.  The purpose of the September 2010 base salary increases for Mr. Donenberg and Dr. Snabes were to recognize these individuals for their increased responsibilities and, in the case of Mr. Donenberg, to bring his base salary closer to the peer 50th percentile.

 

In December 2010, the Compensation Committee determined base salaries for 2011.  Prior to the base salary increases for 2011, Mr. Simes’s base salary of $451,500 was at the peer 25th percentile, Mr. Donenberg’s base salary of $280,000 was at the peer 25th percentile and Dr. Snabes’s base salary of $365,000 was above the peer 75th percentile.  Each of the executives received a 3 percent merit increase to his base salary to reflect a cost of living adjustment and each of Messrs. Simes and Donenberg received an additional 7 percent market adjustment to bring their base salaries closer to the peer 50th percentile.  After these increases, both Mr. Simes’s and Mr. Donenberg’s base salaries are between the peer 25th and 50th percentile and Dr. Snabes’s base salary is still above the peer 75th percentile.

 

In establishing base salaries for 2010 and 2011, the Board of Directors and Compensation Committee considered several factors, including in particular:

 

·                  each executive’s position within the company and their level of responsibility;

 

·                  the ability of the executive to impact key business initiatives;

 

·                  the executive’s individual experience and qualifications;

 

·                  the executive’s tenure with the company;

 

·                  compensation paid to executives of comparable positions by our peer companies;

 

37



Table of Contents

 

·                  an assessment of the risk that the executive would leave our company and the harm to our company’s business initiatives if the executive left;

 

·                  company and individual performance, as compared to specific pre-established objectives in the case of Mr. Simes and Mr. Donenberg, which are described below under the heading “—Annual Discretionary Performance Bonus”;

 

·                  the executive’s current and historical compensation levels; and

 

·                  our cash position and anticipated ability to raise any necessary additional financing.

 

Payout of Certain Accrued Vacation Balances.  The “Salary” column for 2010 includes $34,731, $19,885 and $26,154 paid to Mr. Simes, Mr. Donenberg and Dr. Snabes, respectively, for unused accrued vacation time.  In February 2010, the Board of Directors, upon recommendation of the Compensation Committee, approved a one-time cash payment of certain accrued vacation balances and a corresponding change to our vacation policy that limited the number of vacation days any employee could accrue and carry over from one year to the next year.  Under the terms of the payout, each of our employees, including our executives, was paid cash for the number of the employee’s accrued vacation balance days as of December 31, 2009 that exceed the equivalent of one year’s vacation for such employee (if any) multiplied by the employee’s daily base rate of pay at the time of such payment.  No employee, however, received payment for more than one year’s vacation and each employee’s accrued vacation balance was then reduced by the number of days paid out.  The purpose of the accrued vacation payout was to reduce the amount of accrued vacation balances on our balance sheet and soften the impact of the change to our vacation policy limiting the number of vacation days any employee could accrue and carry over from one year to the next year.

 

Annual Discretionary Performance Bonus.  As required under the terms of their employment letter or offer letter agreements, we provide Mr. Simes, Mr. Donenberg and Dr. Snabes the opportunity to earn an annual discretionary performance bonus each year.  The Board of Directors, upon recommendation of the Compensation Committee, typically determines the amount of the bonus each year for each executive based on, among other things, the achievement of performance objectives of our company and individual goals by the executive.  After the completion of each year, the Board of Directors, upon recommendation of the Compensation Committee and excluding the President and Chief Executive Officer who is not present during these discussions, typically determines the amount of annual discretionary performance bonus to be paid to each executive.  Such determination is made after first receiving input from our President and Chief Executive Officer as to his views of the amount of bonus each executive, including himself, should receive.  In determining the final amount of annual discretionary performance bonus to be paid to each executive, the Board of Directors considers the recommendation of the Compensation Committee, the recommendation of our President and Chief Executive Officer, the recommendation of the Compensation Committee’s independent compensation consultant, the Board’s own views as to the achievement of company performance and individual executive goals, the general performance of the company and the executives during the year, regardless of any specific objectives, the performance of the company’s stock price during the year, competitive compensation data and other relevant factors.  The amount of annual cash bonuses paid to our executives is highly discretionary and has been highly variable from year to year.  In December 2010, the Board of Directors delegated to the Compensation Committee the authority to determine annual cash bonuses to our executives for 2010 performance.  The Board of Directors did this since there was a full discussion of such matters at the regular Board meeting in December and it made sense at the time to delegate the final bonus decision to the Compensation Committee in order to streamline the process.

 

38



Table of Contents

 

Annual discretionary bonuses made to our named executive officers for 2010 were as follows:

 

Named Executive Officer

 

2010 Annual
Bonus Payment

 

2010 Annual Bonus As
Percent of Base Salary

 

Final
Incentive Percentage

 

Stephen M. Simes

 

$

270,900

 

60%

 

100% of target

 

Phillip B. Donenberg

 

112,000

 

40%

 

100% of target

 

Michael C. Snabes, M.D., Ph.D.

 

109,500

 

30%

 

75% of target

 

 

The bonus payouts to Mr. Simes and Mr. Donenberg were based primarily on their achievement of certain pre-established goals and objectives.  The goals and objectives, percentage bonus opportunity and actual scoring for Mr. Simes were as follows:

 

Goal/Objective
Category

 

Percentage Bonus
Opportunity

 

Percentage
Bonus Awarded

 

Supporting Detail for Actual
Percentage Bonus Awarded

Clinical

 

Up to 50%

 

25%

 

Progress in LibiGel Phase III clinical program and obtained three FDA Orphan drug designations for cancer vaccines and continued to advance cancer vaccine development program at a minimal cost to BioSante

Financial

 

Up to 40%

 

40%

 

Successfully raised additional financing in March 2010 and June 2010 registered direct offerings

Corporate Development

 

Up to 40%

 

5%

 

Entered into transaction for the development of oncolytic virus technology in which BioSante received an up-front payment and the right to receive milestone and royalty payments

Corporate/Corporate Relations

 

Up to 20%

 

20%

 

Successfully recruited additional BioSante personnel, and engaged in significant investor relations and public relations activities

 

The goals and objectives, percentage bonus opportunity and actual scoring for Mr. Donenberg were as follows:

 

Goal/Objective
Category

 

Percentage Bonus
Opportunity

 

Percentage
Bonus Awarded

 

Supporting Detail for Actual
Percentage Bonus Awarded

Corporate Development

 

Up to 100%

 

5%

 

Entered into transaction for the development of oncolytic virus technology in which BioSante received an up-front payment and the right to receive milestone and royalty payments

Financial

 

Up to 40%

 

40%

 

Successfully raised additional financing in March 2010 and June 2010 registered direct offerings

Corporate/Corporate Relations

 

Up to 20%

 

20%

 

Assumed lead role in Human Resources function; successfully recruited additional BioSante personnel, and engaged in significant investor relations and public relations activities

Management/Accounting and Internal/External Reporting

 

Up to 5%

 

5%

 

Successful negotiation of significant fee waivers and savings, enhanced corporate governance and internal control efforts and no significant accounting issues

Other

 

Not specified

 

5%

 

Successful receipt of qualifying therapeutic discover 48D grant

 

39



Table of Contents

 

With respect to the actual bonus paid to each of Mr. Simes and Mr. Donenberg, the Compensation Committee determined that an “at target” payout equal to 100 percent of their incentive target percentage of base salary (representing 60% and 40% of their base salaries, respectively) was appropriate in light of not only their achievements compared to the pre-established goals and objectives but also the progress the company made with respect to the LibiGel® clinical development program during 2010.

 

The bonus payout to Dr. Snabes was neither formulaic nor based on pre-established goals and objectives.  It was determined by the Compensation Committee on a purely discretionary, post ad hoc basis based on an objective analysis of his 2010 performance and results.  The bonus payout to Dr. Snabes was based, in large part, on his strategic role in connection with the LibiGel® clinical development program and the progress of that program during 2010.

 

The Board of Directors, upon recommendation of the Compensation Committee, intends to adopt a more formal annual bonus plan for 2011.  It is anticipated that the incentive target under the plan for 2011 for each named executive officer will be as set forth in the table below, as well as the threshold, target and maximum annual bonus opportunity.

 

 

 

Incentive Target

 

Annual Bonus Opportunity for Each Executive

 

Named Executive Officer

 

(Percent of
Base Salary)

 

Threshold
(50% of Target)

 

Target
(100% of Target)

 

Maximum
(150% of Target)

 

Stephen M. Simes

 

60%

 

$

149,010

 

$

298,020

 

$

447,030

 

Phillip B. Donenberg

 

40%

 

61,600

 

123,200

 

184,800

 

Michael C. Snabes, M.D., Ph.D.

 

40%

 

75,200

 

150,400

 

225,600

 

 

Consistent with our philosophy that executives with greater roles and responsibilities associated with achieving our company’s performance objectives should bear a greater proportion of the risk that those objectives are not achieved and should receive a greater proportion of the reward if the objectives are met or surpassed, our President and Chief Executive Officer has the highest incentive target and our two Senior Vice Presidents have the next highest incentive target.  The incentive targets of all of our executive officers are at the 50th percentile of comparable positions of companies in our peer group, which is consistent with our philosophy that we target base compensation and total compensation at the 50th percentile of companies in our peer group, except in the case of Dr. Snabes, whose incentive target is at the 75th percentile compared to the incentive targets of executives with comparable positions at companies in our peer group.

 

Each executive’s bonus payment under the 2011 plan will be determined by multiplying the executive’s target bonus amount for the year (the executive’s incentive target times his base salary) by a payout percentage determined based primarily on the achievement of corporate and, to a lesser extent, individual performance objectives.  The maximum payout percentage is 150 percent of target and the minimum threshold payout percentage is 50 percent of target, with no payout for performance below the minimum threshold payout percentage of 50 percent of target.

 

401(k) Savings Plan.  We maintain a 401(k) Savings Plan under which all participant employees, including executive officers, may voluntarily contribute up to 100% of their plan compensation (subject to certain IRS limits) as pre-tax 401(k) deferrals.  We may make discretionary matching contributions to this plan and in 2010 we made matching contributions equal to 50% of each participants 401(k) deferrals.

 

40



Table of Contents

 

Perquisites and Personal Benefits.  It is generally our policy not to extend perquisites and other benefits to our executive officers that generally are not available to our employees.  The only perquisites that we provide to our executives are those that are required under the terms of their employment letter and offer letter agreements.  Each of our executives receives a monthly auto allowance.  In addition, Mr. Simes and Mr. Donenberg receive reimbursement for supplemental life insurance and excess long-term disability insurance premiums and taxes associated with the premiums.  We are required to provide these benefits to our executives under their employment letter and offer letter agreements.  We believe the cost of providing such benefits is not material.  Our executives also receive benefits, which are received by our other employees, including 401(k) matching contributions, health, dental and life insurance benefits, and reimbursement for certain minimal health club costs ($50/month) to encourage physical activity and good health.  We do not provide supplemental retirement benefits, pension arrangements or post-retirement health coverage for our employees, including our executives.  We also do not provide any nonqualified defined contribution or other deferred compensation plans.

 

Indemnification Agreements.  We have entered into agreements with all of our named executive officers under which we are required to indemnify them against expenses, judgments, penalties, fines, settlements and other amounts actually and reasonably incurred, including expenses of a derivative action, in connection with an actual or threatened proceeding if any of them may be made a party because he or she is or was one of our executive officers.  We will be obligated to pay these amounts only if the executive officer acted in good faith and in a manner that he or she reasonably believed to be in or not opposed to our best interests.  With respect to any criminal proceeding, we will be obligated to pay these amounts only if the executive officer had no reasonable cause to believe his or her conduct was unlawful.  The indemnification agreements also set forth procedures that will apply in the event of a claim for indemnification.

 

Grants of Plan-Based Awards

 

The table below provides information concerning grants of plan-based awards to each of our named executive officers during the year ended December 31, 2010.  Such plan-based awards were granted to our named executive officers under the BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan.  The material terms of these awards and the material plan provisions relevant to these awards are described in the notes to the table below or in the narrative following the table below.  Options also were granted to our named executive officers subsequent to December 31, 2010 in January 2011.  The material terms of these awards are described in the narrative following the table below.  During the year ended December 31, 2010, we did not grant any non-equity incentive plan awards, equity incentive plan awards or stock awards, in each case, within the meaning of the SEC rules.

 

GRANTS OF PLAN-BASED AWARDS - 2010

 

 

 

 

 

All Other
Option Awards:
Number of

 

Exercise or
Base Price

 

Grant Date
Fair Value

 

Name

 

Grant
Date(1)

 

Securities Underlying
Options(#)(2)

 

of Option
Awards ($/Sh)

 

Stock and Option
Awards ($)(3)

 

Stephen M. Simes

 

02/02/10

 

150,000

 

$

1.54

 

$

156,000

 

Phillip B. Donenberg

 

02/02/10

 

100,000

 

1.54

 

104,000

 

Michael C. Snabes, M.D., Ph.D.

 

02/02/10

 

25,000

 

1.54

 

26,000

 

 

41



Table of Contents

 


(1)         The grant date is the date on which the Board of Directors met to approve the option grant.

 

(2)         Represents an option granted under the BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan, the material terms of which are described in more detail below under the heading “—BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan.”  The option has a ten-year term and vests over a three-year period, with one-third of the underlying shares vesting on each of February 2, 2011, February 2, 2012 and February 2, 2013, so long as the individual remains an employee of our company as of such date.

 

(3)         We refer you to note (3) to the Summary Compensation Table for a discussion of the assumptions made in calculating the grant date fair value of the option awards.

 

BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan.  Under the terms of the BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan, our named executive officers, in addition to other employees and individuals, are eligible to receive equity-based incentive awards, such as stock options.  Although the 2008 plan is an “omnibus” plan that permits the grant of equity-based incentive awards besides stock options, such as restricted stock, restricted stock units, stock appreciation rights, performance units and stock bonuses, to date, only incentive and non-statutory stock options have been granted.

 

The 2008 plan contains both an overall limit on the number of shares of our common stock that may be issued, as well as individual and other grant limits.  Under the terms of the 2008 plan, no more than 4,000,000 shares of our common stock may be issued pursuant to the plan or the exercise of incentive options and no more than 1,500,000 shares of our common stock may be issued or issuable in connection with restricted stock grants, stock unit awards, performance awards and stock bonuses, in each case subject to adjustment and certain exceptions.  In addition, shares subject to outstanding awards granted under our 1998 plan also become available under the 2008 plan, but only to the extent that such outstanding awards are forfeited, expire or otherwise terminate without the issuance of such shares.  In February 2011, the Board of Directors, upon recommendation of the Compensation Committee, approved a new amended and restated 2008 plan that, among other things, increases the number of shares of our common stock available for issuance under the plan to 6,000,000, subject to approval by our stockholders at the Annual Meeting.  See “Proposal No. 2 —Approval of BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan.”

 

Incentive stock options must be granted with a per share exercise price equal to at least the fair market value of a share of our common stock on the date of grant.  For purposes of the 2008 plan, the fair market value of our common stock is the closing sale price of our common stock, as reported by the NASDAQ Stock Market.  We set the per share exercise price of all stock options granted under the plan at an amount equal to the closing sale price of our common stock on the date of grant.

 

Except in connection with certain specified changes in our corporate structure or shares, the Compensation Committee and the Board of Directors may not, without prior approval of our stockholders, seek to effect any re-pricing of any previously granted, “underwater” option by amending or modifying the terms of the option to lower the exercise price, canceling the underwater option in exchange for (1) cash; (2) a replacement option having a lower exercise price; or (3) other incentive award, or repurchasing the underwater options and granting new incentive awards under the 2008 plan.  For purposes of the 2008 plan, an option is deemed to be “underwater” at any time when the fair market value of our common stock is less than the exercise price.

 

Options will become exercisable at such times and in such installments as may be determined by the Compensation Committee or the Board of Directors, as the case may be, provided that options may not be exercisable after 10 years from their date of grant.  Historically, we generally provided for the

 

42



Table of Contents

 

vesting of stock options granted to executives in equal annual installments over a three-year period commencing on the one-year anniversary of the date of grant.  However, options granted to our executives in January 2011 and options granted to our new employees thereafter will vest in equal annual installments over a four-year period.

 

Optionees may pay the exercise price of stock options (1) in cash; (2) by using a broker-assisted cashless exercise procedure pursuant to which the optionee, upon exercise of an option, irrevocably instructs a broker or dealer to sell a sufficient number of shares of our common stock or loan a sufficient amount of money to pay all or a portion of the exercise price of the option and/or any related withholding tax obligations and remit such sums to us and directs us to deliver stock certificates to be issued upon such exercise directly to such broker or dealer; or (3) by using a cashless exercise procedure pursuant to which the optionee surrenders to us shares of our common stock either underlying the option or that are otherwise held by the optionee.

 

Under the terms of the 2008 plan, unless otherwise provided in a separate agreement, if an executive’s employment or service with our company terminates for any reason, the unvested portion of the option will immediately terminate and the executive’s right to exercise the then vested portion of the option will:

 

·                  immediately terminate if the executive’s employment or service relationship with our company terminated for “cause”;

 

·                  continue for a period of one year if the executive’s employment or service relationship with our company terminated as a result of the executive’s death or disability; or

 

·                  continue for a period of 90 days if the executive’s employment or service relationship with our company terminated for any reason, other than for cause or upon death or disability.

 

As set forth in the 2008 plan, the term “cause” will be as defined in any employment or other agreement or policy applicable to the executive or, if no such agreement or policy exists, will mean (1) dishonesty, fraud, misrepresentation, embezzlement or deliberate injury or attempted injury, in each case related to us or any subsidiary; (2) any unlawful or criminal activity of a serious nature; (3) any intentional and deliberate breach of a duty or duties that, individually or in the aggregate, are material in relation to the overall duties; or (4) any material breach of any employment, consulting, confidentiality or non-compete agreement entered into with us or any subsidiary.

 

As described in more detail under the heading “—Potential Payments Upon Termination or Change in Control,” if there is a change in control of our company, then, under the terms of the 2008 plan, unless otherwise provided by the Compensation Committee or the Board of Directors in its sole discretion either in the agreement evidencing an incentive award at the time of grant or at any time after the grant of an incentive award, all options and stock appreciation rights will become immediately exercisable in full and will remain exercisable for the remainder of their terms, regardless of whether the holder to whom such option and stock appreciation rights have been granted remains in the employ or service of BioSante or any subsidiary, all outstanding restricted stock awards will become immediately fully vested and non-forfeitable; and any conditions to the payment of stock unit awards or restricted stock units, performance awards or units and stock bonuses will lapse.

 

43



Table of Contents

 

As described in more detail under the heading “Proposal No. 2 —Approval of the BioSante Pharmaceuticals, Inc. Second Amended and Restated 2008 Stock Incentive Plan,” the Board of Directors has amended the 2008 plan, subject to stockholder approval.

 

BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan.  The terms of the BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan are substantially similar to the terms of our 2008 plan, except that under the 1998 plan, only stock options, stock awards and stock units could be granted.  No future awards may be granted under the 1998 plan.

 

2010 Plan-Based Awards.  In February 2010, the Board of Directors, upon recommendation of the Compensation Committee, granted Mr. Simes, Mr. Donenberg and Dr. Snabes an option to purchase 150,000, 100,000 and 25,000, respectively, shares of our common stock at an exercise price of $1.54 per share, which represented the fair market value of our common stock, as determined under the 2008 plan, on the date of grant.  In determining the number of stock options to grant each of the executives, the Board of Directors took into consideration several factors, including in particular:

 

·                  each executive’s position within the company and level of responsibility;

 

·                  the executive’s individual experience and qualifications;

 

·                  the executive’s tenure with the company;

 

·                  the peer group data gathered by BDO Seidman, the Compensation Committee’s compensation consultant at the time;

 

·                  an assessment of the risk that the executive would leave our company and the harm to our company’s business initiatives if the executive left;

 

·                  the fact that most of the executives’ then currently outstanding options to purchase shares of our common stock were out-of-the-money; and

 

·                  the recommendation of BDO Seidman and Mr. Simes.

 

2011 Plan-Based Awards.  In December 2010 but effective as of the first business day in 2011, the Compensation Committee granted Mr. Simes, Mr. Donenberg and Dr. Snabes an option to purchase 650,000, 270,000 and 120,000, respectively, shares of our common stock at an exercise price of $1.66 per share, which represented the fair market value of our common stock, as determined under the 2008 plan, on the date of grant (January 3, 2011).  In determining the number of stock options to grant each of the executives, the Compensation Committee took into consideration several factors, including in particular:

 

·                  each executive’s position within the company and the level of responsibility;

 

·                  the executive’s individual experience and qualifications;

 

·                  the executive’s tenure with the company;

 

·                  the potential retention value and motivational impact that a significant equity grant would have on BioSante’s officers at that time;

 

44



Table of Contents

 

·                  the peer group data gathered by Radford, the Compensation Committee’s compensation consultant, which data indicated that the option grants as measured by their long-term incentive value were at the peer 50th percentile for Mr. Simes, the 75th percentile for Mr. Donenberg and between the peer 25th and 50th percentile for Dr. Snabes, and that the option grants as a percent of company were above the peer 75th percentile for each of Messrs. Simes and Donenberg and between the 50th and 75th percentile for Dr. Snabes;

 

·                  an assessment of the risk that the executive would leave our company and the harm to our company’s business initiatives if the executive left;

 

·                  the fact that most of the executives’ then currently outstanding options to purchase shares of our common stock were out-of-the-money; and

 

·                  the recommendations of Mr. Simes with respect to all executives other than himself and the recommendations of Radford, the Compensation Committee’s compensation consultant, with respect to all executives.

 

With respect to the vesting of the stock options, the Compensation Committee decided to extend the vesting of the annual stock options from over a three-year period to over a four-year period to increase the retention value of the options and to acknowledge the often lengthy clinical development and regulatory approval processes involved in pharmaceutical product development.

 

Other Information Regarding Plan-Based Awards.  Under a provision contained in Mr. Simes’s and Mr. Donenberg’s employment letter agreements, upon the termination of their employment by us without cause, all stock options then held by them would be accelerated and all such options would become fully vested and immediately exercisable for a period of one year after the termination date, as described in more detail under the heading “—Potential Payments Upon Termination or Change in Control.”  Dr. Snabes does not have a similar provision in his offer letter agreement or change in control and severance agreement.

 

Outstanding Equity Awards at Fiscal Year End

 

The table below provides information regarding unexercised stock option awards for each of our named executive officers that remained outstanding at December 31, 2010.  We did not have any equity incentive plan awards or stock awards, each within the meaning of the SEC rules, outstanding at December 31, 2010.  As mentioned earlier, additional options were granted to our named executive officers in January 2011 which are not reflected in the table.

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END - 2010

 

 

 

Option Awards

 

Name

 

Number of Securities
Underlying
Unexercised Options
(#) Exercisable

 

Number of Securities
Underlying Unexercised
Options (#)

Unexercisable(1)

 

Option Exercise
Price ($)

 

Option
Expiration
Date

 

Stephen M. Simes

 

71,407

 

 

$

4.00

 

04/06/2011

 

 

 

108,507

 

 

3.40

 

09/26/2012

 

 

 

126,667

 

 

2.10

 

05/29/2013

 

 

 

250,000

 

 

2.775

 

01/11/2017

 

 

 

66,666

 

33,334

(2)

3.995

 

01/14/2018

 

 

 

100,000

 

200,000

(3)

1.51

 

02/01/2019

 

 

45



Table of Contents

 

 

 

Option Awards

 

Name

 

Number of Securities
Underlying
Unexercised Options
(#) Exercisable

 

Number of Securities
Underlying Unexercised
Options (#)

Unexercisable(1)

 

Option Exercise
Price ($)

 

Option
Expiration
Date

 

 

 

 

150,000

(4)

1.54

 

02/01/2020

 

Phillip B. Donenberg

 

21,547

 

 

4.00

 

04/06/2011

 

 

 

37,564

 

 

3.40

 

09/26/2012

 

 

 

79,166

 

 

2.10

 

05/29/2013

 

 

 

25,000

 

 

3.715

 

07/18/2015

 

 

 

25,000

 

 

3.715

 

07/18/2015

 

 

 

62,500

 

 

3.87

 

03/15/2016

 

 

 

50,000

 

 

2.775

 

01/11/2017

 

 

 

40,000

 

20,000

(2)

3.995

 

01/14/2018

 

 

 

41,666

 

83,334

(3)

1.51

 

02/01/2019

 

 

 

 

100,000

(4)

1.54

 

02/01/2020

 

Michael C. Snabes, M.D., Ph.D.

 

50,000

 

 

4.43

 

03/19/2017

 

 

 

66,666

 

33,334

(5)

4.09

 

04/13/2018

 

 

 

16,666

 

33,334

(3)

1.51

 

02/01/2019

 

 

 

 

25,000

(4)

1.54

 

02/01/2020

 

 


(1)         Upon the occurrence of a change in control, the unvested and unexercisable options described in this table will be accelerated and become fully vested and immediately exercisable as of the date of the change in control.  For more information, we refer you to the discussion under the heading “—Potential Payments Upon Termination or Change in Control.”  Under a provision contained in Mr. Simes’s and Mr. Donenberg’s employment letter agreements, upon the termination of their employment by us without cause, all stock options then held by them would be accelerated and all such options would become fully vested and immediately exercisable for a period of one year after the termination date, as described in more detail under the heading “—Potential Payments Upon Termination or Change in Control.”

 

(2)         This option vests over a three-year period, one-third of the underlying shares vesting on each of January 15, 2009, January 15, 2010 and January 15, 2011, so long as the executive remains an employee or consultant of our company as of such date.

 

(3)         This option vests over a three-year period, one-third of the underlying shares vesting on each of February 2, 2010, February 2, 2011 and February 2, 2012, so long as the executive remains an employee or consultant of our company as of such date.

 

(4)         This option vests over a three-year period, one-third of the underlying shares vesting on each of February 2, 2011, February 2, 2012 and February 2, 2013, so long as the executive remains an employee or consultant of our company as of such date.

 

(5)         This option vests over a three-year period, one-third of the underlying shares vesting on each of March 14, 2009, March 14, 2010 and March 14, 2011, so long as the executive remains an employee or consultant of our company as of such date.

 

Options Exercised and Stock Vested During Fiscal Year

 

None of our named executive officers exercised stock options during the year ended December 31, 2010.  We do not have any outstanding stock awards and thus did not have any stock awards vest during the year ended December 31, 2010.

 

46



Table of Contents

 

Potential Payments Upon Termination or Change in Control

 

General.  We have entered into agreements with each of Mr. Simes, Mr. Donenberg and Dr. Snabes, which may require us to provide certain payments to the executive upon a termination of his employment or change in control of our company.  Whether an executive receives a payment and the amount of such payment, if applicable, depends upon the triggering event.  For more information regarding these agreements, we refer you the discussion under the headings “—Summary of Cash and Other Compensation—Simes Employment Letter Agreement,” “—Summary of Cash and Other Compensation—Donenberg Employment Letter Agreement” and “—Summary of Cash and Other Compensation—Snabes Offer Letter and Change of Control and Severance Agreement.”  In addition, our equity-based compensation plans also provide benefits as a result of a change in control of our company.

 

Termination by BioSante for Cause.  If the employment of any of our executives is terminated by us for “cause,” the executive would be entitled to be paid his annual base salary, car allowance and any out-of-pocket expenses incurred through the date of his termination and any amounts the executive would be entitled to under any company benefit plan.  For purposes of Mr. Simes’s and Mr. Donenberg’s agreements, “cause” means any of the following: (1) dishonesty or fraud; (2) theft or embezzlement of our assets; (3) a violation of law involving moral turpitude; (4) repeated and willful failure to follow instructions of the Board of Directors provided that the conduct has not ceased or the offense cured within 30 days following written warning from us; and (5) conviction of willfully engaging in illegal conduct constituting a felony or gross misdemeanor under federal or state law which is materially and demonstrably injurious to the company or which impairs the executive’s ability to substantially perform his duties for the company.  For purposes of Dr. Snabes’s agreement, “cause” means any of the following: (1) dishonesty or fraud; (2) theft or embezzlement of our assets; (3) any unlawful or criminal activity of a serious nature; (4) breach of any terms of his employee confidentiality and assignment of inventions agreement; (5) failure to carry out the duties of his position in a competent manner; and (6) failure to comply with our policies and procedures.  The agreements also provide that the executive must abide by certain non-competition provisions for one year after termination for cause.  Under the terms of our equity-based compensation plans, if an executive’s employment is terminated by us for “cause,” the executive’s outstanding stock options will immediately terminate and may not then be exercisable.

 

Termination by BioSante Without Cause.  Under the terms of each of Mr. Simes’s and Mr. Donenberg’s employment letter agreements, if Mr. Simes’s or Mr. Donenberg’s employment is terminated by us without cause or if in the case of Mr. Simes, we give notice of our intent not to renew his employment agreement, the executive would be entitled to be paid his annual base salary, car allowance and any out-of-pocket expenses incurred through the date of termination.  Additionally, the executives would be entitled to receive:

 

·                  a severance payment, which would be paid in one lump sum in the case of Mr. Simes, and in 12 equal monthly installments in the case of Mr. Donenberg, equal to, in the case of Mr. Simes, the sum of his annual base salary, most recent annual bonus and annual car allowance, and in the case of Mr. Donenberg, his annual base salary at the time of termination;

 

·                  continued term life and disability insurance at our expense, which, in the case of Mr. Simes, would be for a period of one year from the date of his termination or the remaining term of his agreement, whichever is longer, and in the case of Mr. Donenberg,

 

47



Table of Contents

 

would be for a period of one year from the date of his termination, unless in either case the executive obtains full-time employment;

 

·                  continued participation by the executive and his family at our expense in our group health and dental insurance programs, which in the case of Mr. Simes, would be for a period of one year from the date of his termination or the remaining term of his agreement, whichever is longer, and in the case of Mr. Donenberg, would be for a period of one year from the date of his termination, unless in either case the executive becomes eligible to participate in another employer’s corresponding group insurance plans;

 

·                  in the case of Mr. Simes, provision of outplacement services up to a maximum amount of $30,000 and use of an office and reasonable secretarial support for one year, unless Mr. Simes becomes otherwise employed within such period; and

 

·                  payment for all unused vacation days accrued to the date of termination.

 

In addition, in the event we terminate Mr. Simes’s or Mr. Donenberg’s employment without cause, all outstanding stock options then held by the executive at such time will become immediately exercisable and the executive will have one year from the date following his termination of employment to exercise such options.

 

If Dr. Snabes’s employment is terminated by us without cause, Dr. Snabes would be entitled to be paid his annual base salary, car allowance, any out-of-pocket expenses incurred through the date of termination and payment for all unused vacation days accrued to the date of termination.  In addition, Dr. Snabes would receive six months of his annual base salary at the time of termination paid in accordance with our normal payroll practices.  Under the terms of our equity-based compensation plans, Dr. Snabes would have three months to exercise any options outstanding and vested at the time of termination.

 

Termination by Executive for Good Reason.  Under the terms of each of Mr. Simes’s and Mr. Donenberg’s employment letter agreements, Mr. Simes or Mr. Donenberg may terminate his agreement upon 30 days written notice to us for “good reason.”  For purposes of the agreements, “good reason” means (1) assignment of duties inconsistent with his position or a change in responsibilities, title or office; (2) the failure of us to continue, or the taking of action by us that could adversely affect, benefits plans in which the executive is participating (with some exceptions); (3) reduction of salary or car allowance or failure to increase salary as provided in the agreement; and (4) any other breach by us of the agreement.  If Mr. Simes or Mr. Donenberg terminates his agreement for good reason, then we must provide him the payments and benefits described above under “—Termination by BioSante Without Cause.”  Under the terms of our equity-based compensation plans, all outstanding stock options then held by the executive at such time will remain exercisable to the extent then exercisable for a period of three months.  Mr. Snabes does not have the ability under his agreement to terminate his employment for good reason and receive severance benefits.

 

Termination in the Event of Death or Permanent Disability.  Each of Mr. Simes’s and Mr. Donenberg’s employment letter agreements terminate in the event of the executive’s death or permanent disability.  In the event of death, the executive’s base salary and car allowance will be terminated as of the end of the month in which the executive’s death occurs.  Upon an executive’s “disability,” we can terminate the executive’s employment upon 30 days written notice.  For purposes of the agreements, “disability” means an inability, due to illness, accident or any other physical or mental incapacity, to substantially perform the executive’s duties for a period of four consecutive

 

48



Table of Contents

 

months or for a total of six months in any 12 month period.  Upon termination of an executive’s employment due to disability, the executive will be entitled to receive compensation until the later of (1) the date of termination of employment for disability or (2) the date upon which the executive begins to receive long-term disability insurance benefits.  In addition, in the event the executive’s employment is terminated as a result of the executive’s death or permanent disability, all outstanding stock options then held by the executive at such time will become immediately exercisable and the executive or his estate will have one year from the date of termination of employment to exercise such options.

 

In the event of the termination of Dr. Snabes’s employment as a result of his death or disability, Dr. Snabes (or his estate or heirs) would be entitled to be paid his annual base salary, car allowance, any out-of-pocket expenses incurred through the date of termination and payment for all unused vacation days accrued to the date of termination.  Under the terms of our equity-based compensation plans, Dr. Snabes (or his estate or heirs) would have one year to exercise any options outstanding and vested at the time of termination.

 

Change in Control.  Each of Mr. Simes, Mr. Donenberg and Dr. Snabes has received stock options under the BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan and the BioSante Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan.  Under the terms of such plans, such stock options become fully exercisable following a “change in control” of our company, which is defined under the plans as:

 

·                  the sale, lease, exchange or other transfer of all or substantially all of the assets of our company to a corporation that is not controlled by us;

 

·                  the approval by our stockholders of any plan or proposal for the liquidation or dissolution of our company;

 

·                  certain merger or business combination transactions;

 

·                  more than 50 percent of our outstanding voting shares are acquired by any person or group of persons who did not own any shares of common stock on the effective date of the plan; or

 

·                  certain changes in the composition of the Board of Directors.

 

In order for our executives to receive any other payments or benefits as a result of a change in control of our company, there must be a termination event, such as a termination by us for any reason other than for cause or, in the case of Mr. Simes or Mr. Donenberg, a termination by the executive for good reason.  Such termination event must occur either within the period beginning on the date of the change in control and ending on the last day of the first full calendar month following the second year anniversary date of the change in control or prior to the change in control if the termination of employment was either a condition of the change in control or was at the request or insistence of a person related to the change in control.  For purposes of the change in control provisions, the definition of “good reason” is broader than outside the context of change in control and includes:  (1) our failure to obtain from any successor the assent to assume the employment letter agreements; (2) any purported termination by us of the executive’s employment that is not properly effected; (3) a requirement that the executive be based at any office or location that is more than 30 miles further from the office or location thereof immediately preceding the change in control; and (4) any

 

49



Table of Contents

 

termination by the executive of his employment for any reason during the 13th month after the completion of the change in control.

 

If such a termination event occurs, the executive would be entitled to be paid his annual base salary, car allowance and any out-of-pocket expenses incurred through the date of termination.  Additionally, the executive would be entitled to receive:

 

·                  a severance payment, which would be paid in one lump sum equal to, in the case of Mr. Simes, the sum of: (1) two times his annual base salary, plus (2) his most recent annual bonus, plus (3) his maximum annual bonus (100 percent of base salary) for the year in which the change in control occurs, in the case of Mr. Donenberg, the sum of: (1) 1½ times his annual base salary, plus (2) his maximum annual bonus (100 percent of base salary) for the year in which the change in control occurs, and in the case of Dr. Snabes, the sum of: (1) ½ of his annual base salary, plus (2) his target annual bonus (30 percent of base salary) for the year in which the change in control occurs.

 

·                  in the case of Mr. Simes and Mr. Donenberg, substantially the same health, dental, life and disability insurance benefits the executive received prior to his termination for a period of up to 24 months for Mr. Simes and 18 months in the case of Mr. Donenberg;

 

·                  provision of outplacement services up to a maximum amount of $30,000 in the case of Mr. Simes and Mr. Donenberg and $15,000 in the case of Dr. Snabes;

 

·                  reimbursement for out-of-pocket expenses incurred by the executive on behalf of our company; and

 

·                  payment for all unused vacation days accrued to the date of termination.

 

If any payments to an executive under the agreements or otherwise are considered contingent upon a “change in control” for purposes of Section 280G of the Internal Revenue Code of 1986, and therefore would constitute a “parachute payment” under the Internal Revenue Code, then such payments either would be reduced to the largest amount as will result in no portion of such payments being subject to the tax imposed by Section 4999 of the Internal Revenue Code or would require the executive to pay any additional 20 percent excise tax on the amount of any parachute payment received, whichever is more beneficial to the executive.

 

Potential Payments to Named Executive Officers.  The table below describes the potential payments to each of our executives in the event of a termination of his employment on December 31, 2010 or a change in control of our company on December 31, 2010.  The table below does not include any accrued and unpaid base salary to which the executives also would be entitled.

 

Name

 

Executive Benefits
and Payments

 

Termination
For
Cause

 

Termination
Upon
Death or
Disability

 

Termination
Without
Cause or for
Good
Reason

 

Change in
Control -
No
Termination
Event

 

Change in
Control -
With
Termination
Event

 

Stephen M. Simes

 

Severance Payment

 

$

0

 

$

0

 

$

734,400

 

$

0

 

$

1,444,800

 

 

 

Unvested and Accelerated Stock Options(1)(2)

 

0

 

0

 

0

 

41,000

 

41,000

 

 

 

Term Life and Disability Insurance(3)

 

0

 

0

 

13,248

 

0

 

26,496

 

 

 

Group Health and Dental Plan

 

0

 

0

 

25,488

 

0

 

50,976

 

 

50



Table of Contents

 

Name

 

Executive Benefits
and Payments

 

Termination
For
Cause

 

Termination
Upon
Death or
Disability

 

Termination
Without
Cause or for
Good
Reason

 

Change in
Control -
No
Termination
Event

 

Change in
Control -
With
Termination
Event

 

 

 

Benefits(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

Accrued but Unpaid Vacation

 

135,450

 

135,450

 

135,450

 

0

 

135,450

 

 

 

Outplacement Services

 

0

 

0

 

30,000

 

0

 

30,000

 

 

 

Office Space and Administrative Services(5)

 

0

 

0

 

36,000

 

0

 

0

 

 

 

Total:

 

$

135,450

 

$

135,450

 

$

974,586

 

$

41,000

 

$

1,728,722

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Phillip B. Donenberg

 

Severance Payment

 

$

0

 

$

0

 

$

280,000

 

$

0

 

$

700,000

 

 

 

Unvested and Accelerated Stock Options(1)(2)

 

0

 

0

 

0

 

20,835

 

20,835

 

 

 

Term Life and Disability Insurance(3)

 

0

 

0

 

10,463

 

0

 

15,695

 

 

 

Group Health and Dental Plan Benefits(4)

 

0

 

0

 

25,488

 

0

 

38,232

 

 

 

Accrued but Unpaid Vacation

 

14,625

 

14,625

 

14,625

 

0

 

14,625

 

 

 

Outplacement Services

 

0

 

0

 

0

 

0

 

30,000

 

 

 

Total:

 

$

14,625

 

$

14,625

 

$

330,576

 

$

20,835

 

$

819,387

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Michael C. Snabes, M.D., Ph.D.

 

Severance Payment

 

$

0

 

$

0

 

$

182,500

 

$

0

 

$

292,000

 

 

 

Unvested and Accelerated Stock Options(1)(2)

 

0

 

0

 

0

 

6,833

 

6,833

 

 

 

Accrued but Unpaid Vacation

 

 

 

 

 

 

 

 

 

 

 

 

 

Outplacement Services

 

0

 

0

 

0

 

0

 

15,000

 

 

 

Total:

 

$

0

 

$

0

 

$

182,500

 

$

6,833

 

$

313,833

 

 


(1)         The value of the automatic acceleration of the vesting of unvested stock options held by an executive is based on the difference between: (a) the market price of the shares of our common stock underlying the unvested stock options held by such officer as of December 31, 2010, which is based on the closing sale price of our common stock on December 31, 2010 ($1.64), and (b) the exercise price of the options, which range from $1.51 to $4.43 per share.

 

(2)         In January 2011, we granted options to purchase 650,000, 270,000 and 120,000 shares of our common stock to Mr. Simes, Mr. Donenberg and Dr. Snabes, respectively, at an exercise price of $1.66 per share, which options vest in four equal annual installments on the first, second, third and fourth year anniversary of the date of grant.  The value of the automatic acceleration of the vesting of these stock options is not included in the above table.

 

(3)         The value of the term life and disability insurance is based on our current group plans and any applicable supplemental insurance provided to such executives at the 2010 rates actually paid.

 

(4)         The value of the group health plan benefits is based on premium rates in effect in December 2010.

 

(5)         The value of office space and administration services is based on current market information for the Chicago, Illinois area received from a third party.

 

Required Resignations and Releases; Confidentiality and Other Provisions.  Mr. Simes and Mr. Donenberg have agreed upon any termination of their employment to resign from any and all director, officer, trustee, agent and any other positions with our company or our affiliates, such as our employee benefit plans.  Dr. Snabes must sign a release prior to receiving any change in control or severance benefits.  In addition, certain terms of their agreements will survive any termination of their employment, including the assignment of inventions and confidentiality provisions and in the event of certain terminations, portions of the non-competition provisions.  Finally, any payments made to Mr. Simes and Mr. Donenberg as a result of a “separation of service” under the non-qualified deferred

 

51



Table of Contents

 

compensation rules of Section 409A under the Internal Revenue Code will be suspended for six months, if necessary.

 

52



Table of Contents

 

RELATED PERSON RELATIONSHIPS AND TRANSACTIONS

 


 

Director and Executive Officer Compensation

 

Please see “Director Compensation” and “Executive Compensation” for information regarding the compensation of our directors and executive officers and for information regarding employment, indemnification and other agreements we have entered into with our current and former directors and executive officers.

 

Policies and Procedures Regarding Related Party Transactions

 

The Board of Directors has delegated to the Audit and Finance Committee, pursuant to the terms of a written policy, the authority to review, approve and ratify related party transactions.  If it is not feasible for the Audit and Finance Committee to take an action with respect to a proposed related party transaction, the Board of Directors or another committee of the Board of Directors, may approve or ratify it.  No member of the Board of Directors or any committee may participate in any review, consideration or approval of any related party transaction with respect to which such member or any of his or her immediate family members is the related party.

 

Our policy defines a “related party transaction” as a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we (including any of our subsidiaries) were, are or will be a participant and in which any related party had, has or will have a direct or indirect interest.

 

Prior to entering into or amending any related party transaction, the party involved must provide notice to our finance department of the facts and circumstances of the proposed transaction, including:

 

·                  the related party’s relationship to us and his or her interest in the transaction;

 

·                  the material facts of the proposed related party transaction, including the proposed aggregate value of such transaction or, in the case of indebtedness, the amount of principal that would be involved;

 

·                  the purpose and benefits of the proposed related party transaction with respect to us;

 

·                  if applicable, the availability of other sources of comparable products or services; and

 

·                  an assessment of whether the proposed related party transaction is on terms that are comparable to the terms available to an unrelated third party or to employees generally.

 

If our finance department determines the proposed transaction is a related party transaction and the amount involved will or may be expected to exceed $10,000 in any calendar year, the proposed transaction will be submitted to the Audit and Finance Committee for its prior review and approval or ratification.  In determining whether to approve or ratify a proposed related party transaction, the Audit and Finance Committee will consider, among other things, the following:

 

·                  the purpose of the transaction;

 

53



Table of Contents

 

·                  the benefits of the transaction to us;

 

·                  the impact on a director’s independence in the event the related party is a non-employee director, an immediate family member of a non-employee director or an entity in which a non-employee director is a partner, shareholder or executive officer;

 

·                  the availability of other sources for comparable products or services;

 

·                  the terms of the transaction; and

 

·                  the terms available to unrelated third parties or to employees generally.

 

Related party transactions that involve $10,000 or less must be disclosed to the Audit and Finance Committee but are not required to be approved or ratified by the Audit and Finance Committee.

 

We also produce quarterly reports to the Audit and Finance Committee of any amounts paid or payable to, or received or receivable from, any related party.  These reports allow us to identify any related party transactions that were not previously approved or ratified.  In that event, the transaction will be promptly submitted to the Audit and Finance Committee for consideration of all the relevant facts and circumstances, including those considered when a transaction is submitted for pre-approval.  Under our policy, certain related party transactions as defined under our policy, such as certain transactions not requiring disclosure under the rules of the SEC, will be deemed to be pre-approved by the Audit and Finance Committee and will not be subject to these procedures.

 

54



Table of Contents